

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number
WO 2005/033694 A2

(51) International Patent Classification⁷: **G01N 31/00**,
A01N 43/00, A61K 31/70, C07H 21/02, 21/04, 21/00

(21) International Application Number:
PCT/BE2004/000142

(22) International Filing Date: 6 October 2004 (06.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/508,959 6 October 2003 (06.10.2003) US

(71) Applicant (for all designated States except US): **UNIVERSITEIT GENT** [BE/BE]; Sint-Pietersnieuwstraat 25, B-9000 Gent (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VERBRUGGEN, August** [BE/BE]; Zanddstraat 12, B-9810 Nazareth (BE). **ELEWAUT, Dirk** [BE/BE]; Victor Laureinstraat 21, B-9052 Gent (BE). **WAN, Jun** [CN/BE]; Brouwersstraat 105, B-3000 Leuven (BE).

(74) Agents: **BIRD, William, E.** et al.; Bird Goen & Co., Klein Dalenstraat 42A, B-3020 Winksele (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL ANTISENSE OLIGOMERS AND USE THEREOF

(57) Abstract: The invention relates to the use of a novel type of antisense oligomers for use in the *in vitro* or *in vivo* inhibition of gene expression of a target gene. These oligomers, called exon-bridging oligomers are complementary to those parts of a spliced mRNA which are derived from two adjacent exons in the primary RNA transcript, and are called exon-bridging antisense oligomers. These oligomers have no complementarity to genomic DNA. These oligomers can be used to performs antisense inhibition with less aspecific binding to genomic DNA. The exon-bridging oligomers are suitable for inhibiting Interleukin1 type I Receptor in, for instance, chondrocytes, and are suitable for the prevention or treatment of osteoarthritis.



WO 2005/033694 A2

NOVEL ANTISENSE OLIGOMERS AND USE THEREOF

Field of the invention

The invention relates to methods for modulating gene expression by antisense
5 technology. The invention relates in particular to the inhibition of matrix
degradation in the treatment of osteoarthritis.

Background

Antisense technology has been used for a long time to inhibit the expression of
10 genes. The design of antisense oligonucleotides has largely focused on pre-
spliced mRNA and more in particular on the 5' and 3' splice junctions of an exon.
The possibility that such oligonucleotides may also interfere with genomic DNA,
and as a consequence reduce efficiency or have toxic effects to a cell, has not
been considered in great detail up to now.

15 The success in inhibiting the splicing and translation of a gene by antisense
technology is often variable and several antisense oligomers which span sections
along the entire primary transcript have to be developed and tested in order to
obtain an oligonucleotide which provides sufficient inhibition. Despite the
widespread use of antisense technology there is still a need for more efficient
20 antisense oligonucleotides.

Normal function of a synovial joint depends on proper functioning of all tissues in
this organ. The loaded tissues in weight-bearing joints are articular cartilage and
subchondral bone. Proper function of these tissues, e.g. deformation under load,
25 shock absorption and lubrication of the load-bearing articular surfaces is
dependent on the biochemical composition of their extracellular matrix (ECM). The
homeostasis of this highly specialised ECM is controlled by the articular cartilage
cell: the chondrocyte. In order to maintain an optimal ECM composition,
chondrocytes constantly – and at random – replace the molecular constituents of
30 their extracellular environment. To achieve this, auto/paracrine catabolic and
anabolic growth factor pathways balance each other's activities. In other words, a
constant turnover rate of the ECM is achieved when physiological degradative and

synthetic processes are in equilibrium. The actors of these auto/paracrine pathways, the growth factors, the cytokines and their respective plasma membrane receptors, are produced by the chondrocytes themselves.

In normal healthy cartilage, the Insulin-Like Growth Factor /Insulin-Like Growth
5 Factor I Receptor (IGF1/IGF1R) pathway is responsible for the anabolic activities of the chondrocyte, while the Interleukin-1/Interleukin-1 Receptor type I (IL1/IL1RI) pathway controls chondrocyte catabolic action. Specific receptors that induce intracellular post-signalling activities are responsible for the activity of each pathway. IL1 activities are ensured by functional receptors and are controlled by
10 the production of receptor antagonists or decoy receptors. IL1 (IL1-alpha (IL1A) and IL1-beta (IL1B)) transmits its signal through the cell after binding to the type 1 receptor for IL1 (IL1RI). The presence of a decoy type 2 receptor for IL1 (IL1RII) that is unable to transmit an intracellular signal after IL1 binds to it, offers a mechanism for the chondrocyte to remain in control of too abundant catabolic IL1
15 activity. IL1RII thus functions as a biological mousetrap for IL1. In normal healthy cartilage, IGF-1/IGF1R induced IL1RII overrules the catabolic IL1/IL1RI pathway and controls the homeostasis of the ECM (Wang et al. Arthritis Rheum (2003);48:1281-91)

20 Osteoarthritic (OA) cartilage is characterised by destructive processes, which is known to be a result of the disruption of the equilibrium between the IGF-1/IGF-1R and IL1/IL1RI pathways. Inhibition of the IL1/IL1RI pathway has been suggested using both IL1 inhibitors (such as antibodies) and IL1 receptor antagonists, with varying results.

25

Antisense inhibition of IL1 using antisense has been reported for hematopoietic cells *in vitro* (Manson et al. 1990, *Lymphokine Res.* 9: 35-42), but has not led to further investigations on *in vivo* therapeutic applications.

30 US patent 5,856,099 describes the use of oligonucleotides for the inhibition of IL1RI by antisense technology. The oligonucleotides described therein are complementary to regions in the unspliced mRNA. Oligonucleotides were designed

against the 5' Cap, 5'UTR, start AUG, splice junction regions containing both exon and intron sequence, exonic sequences, and 3' UTR region. Only a very limited number of the designed antisense nucleotides gave a significant inhibition of IL1RI expression (between 46 and 90 %). These oligonucleotides were directed against the 3' UTR of the prespliced mRNA of IL1RI. IC₅₀ values for the optimal oligonucleotide were between 75 and 100 nM, depending on the cell type used. US 5,856,099 demonstrates that, using a classical design of antisense oligonucleotides for the antisense inhibition of IL1RI, a limited number of oligonucleotides are identified which are effective at concentrations of 100 nM or more.

Summary of the invention

The present invention presents a method of designing and using antisense oligomers that allow a more efficient modulation of a target gene. Oligomers are used which are complementary to the spliced mRNA and not to pre-spliced mRNA or genomic DNA. Specificity for spliced mRNA is achieved by targeting those regions in the spliced mRNA which encompass the junction of two consecutive exons obtained after the removal by splicing of at least one intron between two exons from the primary pre-spliced RNA transcript. The use of such antisense oligomers, herein referred to as exon-bridging oligomers, prevents aspecific binding of the oligomer to the genomic DNA of the targeted gene itself. Moreover, the present invention provides methods for further decreasing the interaction of the oligomers with any genomic DNA. Thus, the local distortion of the genome and activation or inhibition of other genes which are located on the genome in the vicinity of the target gene is avoided. Such unwanted gene activation/inhibition can cause undesirable side effects or cell toxicity. Because the exon-bridging oligomers are not scavenged by genomic DNA, the amount of exon-bridging antisense oligomer required to obtain effective inhibition is significantly reduced compared to conventional antisense oligomers. Thus the present invention relates to antisense oligonucleotides that can be used at lower concentrations, can

provide more efficient inhibition and are less likely to cause unwanted effects such as reduced viability of cells being treated with antisense oligonucleotides.

Thus, a first aspect of the present invention relates to exon-bridging probes, which
5 are of use in different applications including, but not limited to the methods described herein, i.e. *in vitro* or *in vivo* modulation of the expression of a target gene in a cell population, more particularly inhibition of a target gene.

According a particular embodiment of the invention, the exon-bridging antisense
10 oligomers of the invention have a length of between 15-30 nucleotides, particularly of 20 nucleotides. A further particular embodiment of the invention relates to exon-bridging antisense oligomers of which the complementary sequence has less than 70% sequence identity with a nucleotide sequence other than the mature mRNA or DNA of said target gene. In another particular embodiment, the invention provides
15 exon-bridging antisense oligomers having a GC content of at least 45%. In another particular embodiment of the invention exon-bridging antisense oligomers are provided wherein the sequences complementary to the 5' and 3' end of the exon-exon boundary of the mRNA of said target gene within the exon-bridging antisense oligomer have a T_m of less than 32-36°C. Additionally or alternatively, the exon-
20 bridging antisense oligomers of the invention do not comprise a sequence of more than 11 consecutive nucleotides which are complementary to the sequence at the 3' end or the sequence at the 5' end of the exon-exon boundary in the mature mRNA of the target gene. Moreover, additionally or alternatively according to the present invention, the exon-bridging antisense oligomers have a sequence which
25 displays at least 70 % sequence identity with the complementary sequence of the cDNA of said target gene.

A further particular embodiment of this aspect of invention relates to exon-bridging antisense oligomers complementary to the mRNA of IL1RI for the inhibition of the
30 expression of the IL1RI gene.

A particular embodiment of this aspect of the invention relates to exon-bridging antisense oligomers directed which bridge exon 02-03, which are particularly suited for use in the methods of the present invention. Thus in particular, the present invention relates to probes having at least 70% sequence identity with the complementary sequence of the cDNA sequence spanning exons 02-03. Even more particularly, the present invention provides an exon-bridging antisense oligomer selected from the group consisting of probe Nos. 6 (SEQ ID NO:6), 7 (SEQ ID NO:7), 8 (SEQ ID NO:8) and 21 (SEQ ID NO:21) described herein and exon-bridging antisense oligomers having at least 70% sequence identity with the sequence of probe NO. 6, 7, 8 or 21 described herein, more particularly exon bridging antisense oligomers which additionally have at least 70% sequence identity with the complementary sequence of the cDNA of the IL1R1 gene corresponding to probes NO.6, 7, 8, or 21.

Another particular embodiment of this aspect of the invention relates to exon-bridging antisense oligomers directed which bridge exon 05-06, which are particularly suited for use in the methods of the present invention. Thus in particular, the present invention relates to probes having at least 70% sequence identity with the complementary sequence of the cDNA sequence spanning exon 05-06. Even more particularly, the present invention provides an exon-bridging antisense oligomer selected from the group consisting of probe No 24 (SEQ ID NO:24) and exon-bridging antisense oligomers having at least 70% sequence identity with the sequence of probe NO. 24 described herein, more particularly exon bridging antisense oligomers which additionally have at least 70% sequence identity with the complementary sequence of the cDNA of the IL1R1 gene corresponding to probes NO. 24.

A second aspect of the present invention relates to a method for the *in vitro* or *in vivo* modulation of the expression of a target gene in a cell population with an antisense oligomer said method characterised in that mature mRNA function is inhibited by contacting the cells with an exon-bridging antisense oligomer directed against said mature mRNA.

According a particular embodiment of the invention, the exon-bridging antisense oligomers used in the method of the invention have a length of between 15-30 nucleotides, particularly of 20 nucleotides.

5

According a particular embodiment of the invention, the method comprises the step of contacting the cells with the exon-bridging oligomers in the absence of a DNA transfecting agent.

- 10 According a particular embodiment of the invention, a method for inhibiting a target gene is provided, wherein the function of all mature mRNAs originating from said target gene is inhibited using one or more exon-bridging antisense oligomers.

- 15 According to a particular embodiment of the invention, a method of inhibition is provided using exon-bridging antisense oligomers wherein the complementary sequence of the exon-bridging antisense oligomer has less than 70% sequence identity with a nucleotide sequence other than the mature mRNA or DNA of said target gene.

- 20 According to a particular embodiment of the invention, a method of inhibition is provided using an exon-bridging antisense oligomer wherein the exon-bridging antisense oligomer has a GC content of at least 45%.

- 25 According to a particular embodiment of the invention, a method of inhibition is provided using an exon-bridging antisense oligomer wherein the sequences complementary to the 5' and 3' end of the exon-exon boundary of the mRNA of said target gene within the exon-bridging antisense oligomer have a T_m of less than 36°C, particularly between 32-36°C.

- 30 According to a particular embodiment of the invention, a method of inhibition is provided using an exon-bridging antisense oligomer wherein the exon-bridging antisense oligomer does not comprise a sequence of more than 11 consecutive

nucleotides which are complementary to the sequence at the 3' end or the sequence at the 5' end of the exon-exon boundary in the mature mRNA of the target gene.

5 According to a particular embodiment of the invention, a method of inhibition is provided using an exon-bridging antisense oligomer wherein wherein the sequence of the exon-bridging antisense oligomer sequence has at least 70 % sequence identity with the complementary sequence of the cDNA of said target gene.

10

According to a particular embodiment of the invention, a method of inhibition is provided using an exon-bridging antisense oligomer, which comprises contacting the cells with 1 to 100 nM, particularly 1 to 10 nM, of the exon-bridging antisense oligomer.

15

According to a particular embodiment of this aspect of the invention, an *in vitro* or *in vivo* method for inhibition of IL1R1 expression is provided by using the exon-bridging antisense oligomers of the present invention directed against the IL1R1 mRNA.

20

According to a particular embodiment of this aspect of the invention, an *in vitro* or *in vivo* method for increasing the synthesis of extracellular matrix compounds in a cell population by inhibiting the expression of IL1RI is provided characterised in that it comprises the step of contacting the cells with an IL1RI exon-bridging antisense oligomer. More particularly, according to the invention, this can be achieved using the antisense oligomers which having a sequence of 15 to 30, more particularly 20 nucleotides, which are complementary to the sequence in the IL1R1 cDNA bridging exons 02-03 or 05-06. Most particularly, the present invention relates to a method of increasing the synthesis of ECM compounds by using probes selected from the group of probes Nos 6 (SEQ ID NO:6), 7 (SEQ ID NO:7), 8 (SEQ ID NO:8), 21 (SEQ ID NO:9) and 24 (SEQ ID NO:24) described herein or exon-bridging antisense oligomers having at least 70% sequence identity

25
30

with the sequence of probe Nos. 6, 7, 8, 21 or 24 described herein, more particularly exon bridging antisense oligomers which additionally have at least 70% sequence identity with the complementary sequence of the cDNA of the IL1R1 gene corresponding to probes Nos. 6, 7, 8, 21 or 24.

5

According to a particular embodiment of this aspect of the invention, a method of inhibiting IL1R1 is provided. It is demonstrated that antisense inhibition at the level of the mature IL1R1 mRNA transcript with exon-bridging antisense oligomers results in an efficient inhibition using lower amounts of oligomers and avoiding possible toxic effects to the treated cells. The present invention more particularly relates to the use of one or more of the exon-bridging antisense oligomers directed against IL1R1 described herein, for the inhibition of IL1R1 in chondrocytes, chondrocyte precursors, fibrochondrocytes, or fibroblasts, more particularly in osteoarthritic chondrocytes either in vitro or in vivo.

15

A particular embodiment of this aspect of the present invention further relates to a method of inhibiting excessive IL1 activity in conditions characterised by excessive signalling through the IL1/IL1R pathway in humans or animals. It is demonstrated that in such conditions, more particularly in osteoarthritis, inhibition of the receptor by the method of the invention has a number of advantages. Moreover, this overcomes the inherent disadvantages associated with ligand-inhibition.

20

25

Thus, according to one embodiment of the invention, exon-bridging probes are used as a medicament for the inhibition of expression of human IL1R1.

Accordingly, another aspect of the invention relates to a pharmaceutical composition comprising one or more exon-bridging antisense oligomers for the inhibition of the expression of a target gene and further comprising at least one pharmaceutically acceptable carrier. More particularly, the invention relates to pharmaceutical compositions comprising one or more of the IL1R1 inhibiting exon-bridging antisense oligomers described herein.

30

A particular embodiment of the pharmaceutical compositions of the present invention are compositions comprising one or more exon-bridging antisense oligomer against IL1R1. More particularly the composition comprises one or more IL1R1 exon-bridging antisense oligomers having a sequence of 15 to 30, more particularly 20 nucleotides, which are complementary to the sequence in the IL1R1 cDNA bridging exons 02-03 or 05-06. Most particularly, the composition comprises one or more IL1R1 exon-bridging antisense oligomers selected from the group consisting of probes Nos 6 (SEQ ID NO:6), 7 (SEQ ID NO:7), 8 (SEQ ID NO:8), 21 (SEQ ID NO:21) and 24 (SEQ ID NO:24) described herein and exon-bridging antisense oligomers having at least 70% sequence identity with the sequence of probe NO. 6, 7, 8, 21 or 24 described herein, more particularly exon-bridging antisense oligomers which additionally have at least 70% sequence identity with the complementary sequence of the cDNA of the IL1R1 gene corresponding to probes NO. 6, 7, 8, 21 or 24.

15

Another aspect of the invention relates to the use of the IL1R1 exon-bridging antisense oligomers of the present invention in the manufacture of a medicament for the treatment or prevention of a disease characterized by a cartilage or osteochondral defect, more particularly osteoarthritis.

20

Another aspect of the invention relates to the use of the IL1R1 exon-bridging antisense oligomers of the present invention in the manufacture of a medicament for the treatment or prevention of a disease selected from the group consisting of neuropathies, such as diabetic neuropathy, immune-mediated damage to the peripheral nervous system, heat hyperalgesia, Guillain-Barre syndrome, AIDS, bone disorders, such as osteoporosis caused by lymphomyeloid proliferative diseases, bone resorption, as occurring in a variety of diseases including osteoporosis, periodontal disease and rheumatoid arthritis, atheromatosis, coronary heart diseases, acute renal failure, asthma and nasal polyposis.

30

Another aspect of the invention relates to a method for producing an exon-bridging antisense oligomer for the inhibition of expression of a target gene comprising the steps of:

- 1) determining the exon-exon boundaries in the sequence of a spliced mRNA of the target gene,
- 2) selecting a sequence with a length between 15 and 30 residues bridging an exon-exon boundary in the spliced mRNA of the target gene, the sequence comprising at its 5' end or 3' end at least 4 residues identical to a sequence 5' of said exon-exon boundary and, optionally said sequence comprising at its 3' or 5' end a maximum of 11 residues identical to the sequence 3' adjacent of the targeted exon-exon boundary in the target mRNA.
- 3) producing an antisense oligomer which consists of a sequence which is has at least 70% sequence identity with a sequence complementary to the sequence selected in step 2.

According to a particular embodiment, the invention relates to a method as described above, wherein step 2 further comprises one or more of the steps selected from the group consisting of:

- a) determining whether the GC content of the sequence determined under (2) is above 45 %,
- b) determining whether the T_m of each of the sequences 3' and 5' of the exon-exon boundary within the sequence is below 32-36°C,
- c) determining whether the oligomer has a sequence identity below 70% with mature mRNA other than the mature mRNA or DNA of the target gene;

And selecting the one or more sequences which fulfil the criteria of one or more of steps a to c.

The concept of the present invention, underlying the design and use of exon-bridging antisense oligomers can be applied to any gene of which the intron exon

structure is known or can be determined. Thus it applies to all eukaryotic genes, but more specifically is of interest for the modulation of mammalian and human genes. The production of multiple gene products from genes which have different splice variants can be inhibited with exon-bridging antisense oligomers directed
5 against two adjacent exons which are common to all splice variants or with a combination of exon-bridging antisense oligomers which target all possible splice variants.

Moreover the concept of the invention can be applied for other methods of
10 inhibiting gene expression based on mRNA inhibition, such as, but not limited to methods of RNA interference, short-hairpin RNA, etc. whereby these methods make use of probes targeting the exon-bridging regions of the mRNA. Most particularly the present invention provides for inhibition of IL1R1 based on using complementary sequences to the sequences spanning the coding exons in the
15 cDNA of the IL1R1 gene.

Detailed description of the invention

Definitions:

The term “**gene**” refers to a DNA sequence comprising several operably linked
20 DNA fragments such as a promoter, a 5' untranslated region (the 5'UTR), a coding region (which may or may not code for a protein), and an untranslated 3' region (3'UTR) comprising a polyadenylation site. The 5'UTR, the coding region and the 3'UTR are transcribed into a primary RNA transcript. Typically, the sequence of the gene comprises both introns (sequence of DNA that is initially transcribed into
25 primary RNA but is cut out of the mature mRNA transcript) and exons (an exon being a sequence of DNA which together with other transcribed exons of the gene, by splicing of the primary transcript, results in the mature mRNA which comprises the coding sequence). The ‘**target gene**’ as used herein refers to the gene of which the expression is targeted and from which the mature mRNA(s) originate
30 (through a process of transcription and splicing) which are used to design the probe(s) of the invention (also referred to as ‘target mature mRNA’).

The term “**gene expression**” relates to the process by which a gene's coded information is converted into the structures present and operating in the cell. Expressed genes include those that are transcribed into mRNA and then translated into protein and those that are transcribed into RNA but not translated
5 into protein (e.g., transfer and ribosomal RNAs).

The term “**sequence identity**” between regions of mRNA or DNA means that, when two particular nucleotide sequences (RNA or DNA) are aligned, the percentage of nucleotides, i.e. the number of positions with identical nucleotides divided by the total number of nucleotides in the particular nucleotide sequence, is
10 higher than 70%, particularly at least 80%, even more particularly at least 90%, most particularly at least 95-99%, most particularly is 100%.

The terms “**complementary**” or “**complementarity**” refer to base pairing between A and T(orU) and between G and C bases in a nucleotide double strand. For example an oligonucleotide with sequence 5'-GGACTT-3' is complementary to an
15 oligonucleotide with sequence 5'-AAGTCC-3'. Complementarity can be also expressed in percentages as the ratio of the number of base pairs where perfect base pairing occurs over the total number of position where base pairing can occur. Within the context of this invention, an oligomer is complementary with the target mature mRNA when base pairing occurs for at least 70%, preferably for at
20 least 80%, even more preferably at for at least 90%, most preferably at for least 95-99%, more specifically for 100% of the oligonucleotide sequence. An oligonucleotide is 100 % complementary when A T(or U) and G C base pairing with the target mature mRNA sequence occurs at every base pair of the oligonucleotide.

25 The term “**primary RNA transcript**” refers to RNA as transcribed from the gene but which has not been spliced yet into mature mRNA.

The term “**mature mRNA**”, “**processed mRNA**” or “**spliced mRNA**” refers to mRNA which has been spliced from the primary RNA transcript

The term “**exon-exon boundary**” refers to the link between two bases in a mature
30 mRNA sequence corresponding to the connection of the 3' end of an exon and the 5' end exon of another exon of the genomic sequence, more particularly the sequence corresponding to the connection between two coding exons. The 5'end

of an exon-exon boundary refers to the sequence 5' and adjacent to the exon-exon boundary which corresponds to the 3' end of an exon in the genomic DNA. The 3' end of the exon-exon boundary refers to the sequence 3' and adjacent to the exon-exon boundary which corresponds to a sequence at the 5' end of the next exon which has been spliced into the mature mRNA.

The term "**oligomer**" refers to a plurality of nucleosides joined together via covalent linkages in a specific sequence from naturally and/or non-naturally occurring nucleobases, and includes oligonucleotides as well as oligonucleosides.

The term "**oligonucleotide**" refers to an oligomer comprising a plurality of nucleosides joined together by phosphorous linkages. The term "**oligonucleoside**" refers to oligomers comprising a plurality of nucleosides joined together by non-phosphorous linkages. The oligomers of the present invention can also comprise different modifications of the side chains and covalent linkages. Possible modifications are discussed in detail, for example, in US patent application 20030148969.

The term "**effective amount**" in the present invention refers the concentration of an antisense oligomer which can modify gene expression, more particularly decrease gene expression, by inhibition of the target mRNA function. An amount is said to be effective when it results in a decreased expression of the gene with at least 30% preferably at least 50%, more preferably at least 70% even more preferably at least 90 %, and most preferably at least 95 %. Expression can be measured for example by comparing the protein concentration of an expressed target gene in untreated cells compared with cells being treated with an antisense oligomer. In a particular embodiment the protein concentration of an expressed target gene is determined by measuring the fluorescence as MFI after binding of an antibody to the expressed protein. This is described in detail in the experimental part of this application.

Alternatively an effective amount of an antisense oligomer is an amount that modifies (increases or decreases) the expression of a gene downstream of the targeted gene. Effective amounts are those amounts that lead to a modification in expression of gene downstream of the targeted gene, by at least 15 %, preferably at least 30 % and more preferably at least 40%. In a particular embodiment of the

invention, the effect of an antisense oligomer directed against IL1RI expression is measured by the increase in expression of genes encoding one or more ECM compounds, such as aggrecan.

Expression level of a gene can also be measured for example by comparing the mRNA concentration of a target gene in untreated cells versus cells being treated with an antisense oligomer. This can be done for example by Northern analysis.

The present invention relates to the use of oligomers for the modulation of gene expression. More particularly, the expression of one or more genes is modulated by specific hybridization of the oligomers of the invention with one or more target nucleic acids, more specifically one or more target mature mRNAs, interfering with the function of the target mature mRNA. Functions of the target mature mRNA primarily relate to translation of protein from the mature mRNA but moreover include translocation of the mature mRNA and any other effects facilitated by the mature mRNA.

In order to solve the problem of specifically and efficiently targetting mature mRNA, the present invention provides the use of exon-bridging antisense oligomers or oligonucleotides. The term **“exon-bridging antisense oligomer”** refers to an antisense oligomer consisting of a 5' and a 3' end, whereby the 5' end is complementary to the 5' end of an exon of a gene and the 3' end is complementary to the 3' end of the preceding exon of that gene in the mature mRNA. An exon-bridging oligomer is therefore complementary to the mature mRNA. Because the sequence of the 5' and 3' end of an exon-bridging oligomer are separated in the genomic DNA sequence and primary RNA transcript by (at least) an intronic sequence, exon-bridging oligomers are not complementary to genomic DNA or primary RNA. The concept of an exon-bridging oligomer is exemplified for the different exon-bridging sequences of human IL1RI in Table 3. The term exon-bridging is not to be confused with the term exon-spanning probes used in the literature, which are longer polynucleotides complementary to genomic DNA and comprising a sequence corresponding to (or complementary to) at least one exon and adjacent intronic sequences.

The present invention relates to the use of exon-bridging oligomers for *in vivo* or *in vitro* modulation of gene expression. The antisense oligomers used in accordance with this invention can be conveniently and routinely made through the well-known
5 technique of solid phase synthesis. Equipment for such synthesis is commercially available, such as, but not limited to for example, the equipment from Applied Biosystems.

According to the present invention, the exon-bridging antisense oligomers used for
10 the specific inhibition of mature mRNA have a length of between 13 and 30 nucleotides and even more preferred between 15 and 22 nucleotides. Particularly suitable according to the present invention are oligomers of 20 nucleotides. The minimal total oligomer strand length to ensure, on a statistical basis, specificity towards a certain mRNA has been calculated to be 13 bases (1). Optionally,
15 oligomers can have a length which exceeds 30 nucleotides when, apart from the exon-bridging sequence, insertions such as internal hairpins or 5' or 3' extending parts, eg for use as a tag, are present. The choice for a particular length of an oligomer can be influenced by considerations such as T_m and GC content.

20 In a particular embodiment, the oligomer of present invention has a sequence which is at least 70%, preferably at least 80%, more preferably at least 90% and most preferably at least 95% identical to a sequence complementary to the target mature mRNA .

25 In another particular embodiment the sequence of the antisense exon-bridging oligomer (or their complementary sequence) shows as little sequence identity as possible with any other part of the genome. Possible interference with unrelated (encoding other mRNAs than the target mature mRNA) genomic DNA or mRNA is minimised or avoided as assessed by NCBI BLAST^R (3-7). Possible interference
30 with mRNA other than the target mRNA is avoided by using those oligomers which complementary sequence is not more than 70 % identical, preferably not more than 60 % identical, more preferably not more than 50 % identical and most

preferably not more than 30 % identical to a sequence other than the target mRNA sequence. Similarly, interference with genomic DNA is avoided by using those oligomers with a sequence or a complementary sequence which is less than 70 % identical, preferably less than 60% identical, more preferably less than 50% identical and most preferably less than 30% identical to a genomic sequence, including regions representing genes (intron, exons, 5' and 3' regulatory sequences), and regions which do not encode genes, so called junk DNA.

In another particular embodiment the antisense oligomers of the invention have a sequence which is complementary to an exon-exon boundary within the 5' half of the spliced mRNA of a gene. Exon-bridging antisense oligomers directed against mRNA sequences corresponding to the first half of the spliced mRNA will more efficiently silence the target gene than those corresponding to the last third.

In another particular embodiment the exon-bridging antisense oligomers of the present invention do not comprise a sequence of more than 11 consecutive nucleotides which are complementary to the 3' or 5' end of the exon-exon boundary in the target mature mRNA.

Additionally or alternatively the oligomers of the present invention have a GC content of at least 45%. Since in general, genes are located on GC rich regions of the genome and merely 20% of the genes have a GC content of more than 45% (Lander et al., 2001, *Nature* **409**:860-921), a higher GC content restricts the chances of non-specific binding to genomic DNA.

Additionally or alternatively the exon-bridging probes can be designed so that the stretches of nucleotides complementary to the 5' and 3' end of the exon-exon boundary in the target mRNA will not anneal to 100% complementary DNA stretches. This can be achieved by ensuring that the 5' and 3' end of the probe have a T_m (melting temperature) of about 32-37° C, depending on the temperature at which inhibition is desired. This T_m provides an unstable annealing at the human body temperature (adjustments can be made for different parts of the body)

or the temperature at which in vitro inhibition in somatic cells is performed. The T_m for short nucleotides is defined by the length and the GC content of the probe (Wallace RB et al., 1979, *Nucleic Acids Res* 6:3543-57). Thus, according to one embodiment of the invention the length of the probes is adjusted to ensure a T_m of less than 32-37°C. Alternatively, for a particular length, the target sequence of the mature mRNA can be selected so as to ensure an appropriate GC content.

Thus, for a sequence complementary to the 5' or 3' end of the exon-exon boundary having a length of 11 nucleotides, the GC content should not be more than 45% (5/11) - 64% (7/11). For a length of 10 nucleotides, the GC content should preferably be no more than 60-80%. Particularly, the length of the exon-bridging probes can be designed so that the 5' and 3' end are limited to 8 nucleotides or less. For these lengths a GC content of up to 100%, will anneal to 100% complementary sense DNA stretches with T_m of 32°C.

15

Additionally or alternatively, the oligomers of the present invention can be designed to ensure that they are devoid of GGG sequences or longer G repeats in order to avoid self-interaction that would lead to self-composed complexes within oligomers, which no longer hybridize to the target mRNA.

20

In another embodiment the oligomers of the present invention are stabilised by a modification such as phosphorothioate. Other types of stabilizing modifications as described in e.g. US application 20030148969 are envisaged within the context of the present invention, provided that these do not affect the ability of the probes to enter and leave the cells.

25

The present invention relates to the use of exon-bridging probes for the *in vitro* or *in vivo* modulation of gene expression, by interfering with mature mRNA function. The use of exon-bridging oligomers ensures a limited binding of the oligomers to genomic DNA, which avoids certain drawbacks of classical antisense oligomers. Local binding of an antisense oligomer to the genome of the target gene can result in local activation or inactivation of neighbouring genes. This can interfere with the

30

desired inhibition or this can also lead to toxicity and death of cells being treated with the antisense oligomer. Moreover, the present invention describes methods of further reducing interference of exon-bridging probes with genomic DNA.

- 5 Thus, in a particular embodiment of the invention exon-bridging antisense oligomers are used of which the complementary sequence has no more than 70% sequence identity with genomic DNA other than the DNA encoding the target mRNA. Preferably, the oligomers are used of which the complementary sequence has less than 85% sequence identity with any genomic DNA sequence. Additionally
10 or alternatively the sequence of the oligomer is designed such that the oligomer contains a sequence of at most 11 consecutive residues which is identical to either sequence 5' or 3' of the exon-exon boundary. Such an oligomer has no more than 11 residues complementary to the exon in the genomic sequence and is unlikely to bind to the genomic DNA corresponding to the target mature mRNA. Additionally
15 or alternatively, the method of the invention is performed using exon-bridging probes of which the sequences complementary to the 5' and 3' end of the exon-exon boundary of the target mRNA have a T_m of less than 32-37°C, depending on the target tissue or on the inhibition conditions. Additionally or alternatively, by performing the *in vitro* or *in vivo* method with exon-bridging oligomers which have a
20 GC content above 45 %, preferably above 60%, non specific hybridisation with non coding parts of the genome (which are poor in GC content) is minimised.

- Specific binding to the target mature or spliced mRNA is achieved by using an exon-bridging oligomer of which complementary sequence has at least 70%
25 sequence identity with the target mature mRNA.

- According to another aspect of the invention, a method of antisense inhibition is provided which requires a limited amount of antisense probe. Due to the reduced binding of exon-bridging oligomers to genomic DNA, less antisense is scavenged
30 and the method can be performed with a limited amount of oligomer. More particularly, *in vitro* inhibition can be obtained with a concentration of an oligomer in the cell culture medium of less than 100 nM, preferably between 1 and 10 nM

and most preferably about 1nM or less. Also for *in vivo* inhibition, a lower amount of one or more exon-bridging oligomers can be administered compared to non exon-bridging oligomers of the prior art in order to achieve the same effect.

5 In a particular embodiment of the invention, the *in vitro* or *in vivo* modulation of gene expression using exon-bridging oligomers which inhibit mature mRNA function, is reversible. Reversal of a biological exon-bridging oligomer effect can be achieved through changes in the environment of the target cells. *In vitro*, mammalian cells can survive and be metabolically active at temperatures between
10 30 and 38°C. For a given T_m value of a probe, increasing or decreasing the environmental temperature above or below that value will affect annealing of the probe to RNA/DNA. The temperature within different parts of the body can also vary. Intra-articular temperatures can vary in between 32 and 38°C (Oosterveld et al., 1992, *Arthritis Rheum.* **35**, 146-51; Oosterveld & Raster, 1994, *Arthritis Rheum.* **37**, 1578-82). The inhibitory effects of an exon-bridging oligomer can be
15 influenced by heating or cooling of the body part to a temperature above or below the T_m of the total probe (which is according to standard practice higher than that of the body part where inhibition is desired).

20 According to a particular embodiment of the *in vitro* method of inhibiting the expression of a target gene with exon-bridging oligomers, the cells are contacted with the probes in the absence of DNA transfecting agents. DNA transfecting agents are often toxic and will reduce the number of living cells in a population which is treated with antisense oligomers. The absence of DNA transfecting agents is also
25 desirable for *in vivo* applications. Nevertheless, it is envisaged within the context of the present invention that transfecting agents or other additives can be used (e.g. such as those described in US application 20030148969).

A particular aspect of the invention relates to the use of exon-bridging probes for
30 the *in vivo* or *in vitro* modulation of gene expression by inhibition of all mature mRNAs of a target gene. Target genes giving rise to more than one mature mRNA include genes where alternative splicing results in splice variants. According to this

aspect of the invention translation of the mature mRNA of the different splice variants is inhibited. Inhibition of the translation of all splice variants is achieved when the targeted exon-exon boundary is common for all splice variants or when several exon-bridging oligomers are used to cover all possible splice variants.

5

According to another aspect, the invention relates to the use of multiple probes for the modulation of gene expression. According to this aspect a combination of different exon-bridging probes, each directed to a different exon-exon boundary in the mature mRNA sequence is used to ensure inhibition of the mature mRNA.

10

The *in vitro* or *in vivo* method of inhibiting the expression of a target gene with exon-bridging oligomers is applicable to a wide variety of cells including human and non-human mammalian cells, including expanding cells or cells which do not divide, such as confluent cell cultures. Cells can be freshly isolated cells from a tissue or can be expanded or passaged cells. In a particular embodiment the *in vitro* method is performed on connective tissue cells, preferably osteochondral cells, more preferably mature chondrocytes and chondrocyte precursors. Cells can be healthy cells or in a particular embodiment osteoarthritic cells.

15

Another aspect of the invention relates to a pharmaceutical composition comprising one or more exon-bridging antisense oligomers with a length between 15 and 30 residues for the inhibition of the expression of a target gene and further comprising at least one pharmaceutically acceptable carrier. Carriers and other additives which are compatible for a pharmaceutical composition comprising antisense oligomers are described in detail in US application US20030148969.

20

Another aspect of the invention relates to a method for producing an exon-bridging antisense oligomer for the modulation of expression of a target gene by inhibition of the corresponding mature mRNA function, wherein the following steps are performed: 1) determining the exon-exon boundaries in the sequence of one or more mature mRNA of said target gene; 2) selecting a sequence with a length between 15 and 30 residues bridging an exon-exon boundary in the spliced mRNA

25

30

of said target gene, such a sequence comprising at its 5' or 3' end at least 4 residues identical to a sequence 5' of said exon-exon boundary and, optionally said sequence comprising at its 3' or 5' end a maximum of 11 residues identical to the sequence 3' adjacent of said exon-exon boundary; 3) producing an antisense
5 oligomer which consists of a sequence which is at least 70% complementary to the sequence selected in step 2.

According to further embodiments of the invention, the method for producing an exon-bridging oligomer can further comprise one or more of the following steps: a)
10 determining whether the GC content of sequence identified in step 1 is above 45 %
b) determining whether the T_m of a sequence complementary to then sequence identified in step 1 is above 37°C, c) determining whether the sequence complementary to the sequence identified in step 1 has a sequence identity of less than 70% with any mature mRNA other than the mature mRNA of the target gene
15 and d) determining whether the T_m of the sequences 5' and 3' end of the exon-exon boundary in the sequence identified in step 1 is below 32-36°C. Oligomers are then produced which correspond to one or more of the criteria determined in steps a) to d) following steps 2 and 3 described above.

20 Another aspect of the invention relates to the use of an exon-bridging antisense oligomer with a length between 15 and 30 residues for depressing cytokine pathways *in vivo* or *in vivo* through the downmodulation or silencing of the appropriate receptors. Such an inhibition of modulation can have important therapeutic consequences in conditions of which the pathogenesis and the
25 progression are dependent of the overexpression of these cytokine pathways. In this context, inhibition of the signals of pathways such as, but not limited to the TNF/TNFR, the IL2/IL2R, the IL11/IL11R, the IL14/IL14R, the IL15/IL15R, are envisaged.

30 Alternatively, the method of the invention can be used for the silencing or modulation of other cell functions, which have a detrimental effect causing

pathological conditions. Examples include the (over)production of metalloproteinases in tissue destruction, COX-2 in inflammation, ...etc.

A particular aspect of the invention relates to the use of an exon-bridging antisense oligomer according to the present invention for the *in vivo* or *in vivo* inhibition of the expression of Interleukin 1 Receptor Type I (referred to as IL1RI).

In a preferred embodiment of the invention IL1RI is human IL1RI. Human IL1RI (hIL1RI) is documented in OMIM entry 147810. The hIL1RI mRNA sequence is accessible via Genbank (NM_000877 or M27492) In these entries the coding sequence for ILR1 starts at nucleotide 83 and ends at nucleotide 1792. The genomic sequence of hIL1RI is presented in Genbank Accession AF531102. Herein the exons are located at nucleotides:

1296-1371 (non coding "exon 0"); 5079-5139 (exon 1); 12129-12363 (exon 2); 12470-12659 (exon 3); 13468-13636 (exon 4); 15953-16018 (exon 5); 19156-19273 (exon 6); 20042-20193 (exon 7); 21942-22085 (exon 8); 22835-23002 (exon 9), 23710-27231 (exon 10) (exon 10 contains coding sequence from 23710 to 24116) (exon 10).

The sequences bridging the above-cited exons in the mRNA of the IL1R1 are the target of the probes of the present invention. Particularly suited in the context of the present invention are the sequence bridging exons 02-03 and the sequence bridging exons 05-06.

Complete or partial cDNA or genomic IL1RI sequences for non-human mammals are determined for e.g. mouse (NM_008362), rat (NM_013123), horse (AB020338) or can be cloned with standard molecular biology techniques, for example with PCR primers designed for conserved regions of the IL1RI receptor.

Oligomers which have been designed for *in vitro* or *in vivo* inhibition of the expression human IL1RI according to the present invention are presented in table 3 and in the examples.

Exon-bridging oligomers for IL1RI from other animals or for any other gene can be designed when the mRNA sequence around the exon-exon boundaries is known.

According to a particular embodiment of the present invention, the sequences bridging the exons of the IL1R1 gene identified within the context of the present

invention can be used for the design of complementary probes which are not classical antisense probe but other inhibitory probes such as short-hairpin RNA or dsRNA. The main requirement for these probes according to the present invention is that it is a sequence with a length between 15 and 30 residues and that it
5 comprises at its 5' or 3' end at least 4 residues identical to a sequence 5' of said exon-exon boundary.

The modulation of IL1RI expression with exon-bridging antisense oligomers can be used for influencing *in vivo* or *in vitro*, the metabolism of extracellular matrix
10 compounds such as type II collagen, aggrecan and fibronectin. Thus, in one aspect the invention relates to the use of exon-bridging antisense oligomers for the treatment or prevention of a disorder caused or manifested by an excessive IL1RI activation or expression.

15 A particular embodiment of the invention relates to the use of the exon-bridging probes of the invention in the treatment or prevention of a cartilage or osteochondral defect, a defect of joint related tissues and defects of other tissues of a fibrocartilage nature such as intervertebral discs, as well as in the formation of bone or cartilage in other indications, e.g. cosmetic surgery.

20

According to a particular embodiment, the present invention relates to the modulation of IL1RI in order to control the excessive Interleukin-1 (IL1) signalling via Interleukin-1 Receptor type I (IL1RI) in chondrocytes which plays an important role in osteoarthritis (OA). Based on the determination of the different factors
25 regulating the production of ECM in healthy and osteoarthritic chondrocytes, it was established that the IL1/IL1R pathway is the most promising target for therapeutic activity. Increasing growth factor activity would make no sense as the IGF-1/IGF1R pathway is already stimulated in OA tissue, and does not result in an accumulation of ECM compounds in the cell associated matrix (CAM) while newly
30 synthesised ECM products are readily degraded in the presence of an activated IGF/IGF1R pathway. It can be anticipated that the inhibition of IL1/IL1RI pathway by downregulating IL1 levels would be only partially successful when the

upregulation of the CAM is desired. Remaining levels of IL1 would still result in an unacceptable amount of receptor activation. It is demonstrated that using the oligomers of the present invention directed against mature mRNA of IL1RII, production of ECM compounds, more particularly aggrecan is completely restored.

- 5 The low price and fast and simple manufacture of oligonucleotides are important advantages of antisense technology compared to the time and efforts needed for the development of small inhibitory molecules, inhibitory antibodies or inhibitory soluble receptors.

10 According to the present invention, excessive IL1/IL1RI pathway activity can efficiently be inhibited by the use of exon-spanning probes directed against IL1RI mature mRNA. Moreover, the use of the exon-spanning probes of the invention minimizes the risk of interaction with genomic DNA which could negatively affect other cellular processes.

- 15 Thus, one aspect of the invention relates to the use of an exon-bridging antisense oligomer with a length between 15 and 30 residues for the manufacture of a medicament for the treatment or prevention of a disorder caused or manifested by an excessive IL1RI expression. More particularly, the present invention relates to the use of exon-bridging probes for the inhibition of IL1RI expression in
- 20 osteoarthritis. However, other applications of the IL1RI-directed probes of the present invention include (but are not limited to) neuropathies such as diabetic neuropathy, immune-mediated damage to the peripheral nervous system, heat hyperalgesia, Guillain-Barre syndrome, AIDS, bone disorders such as osteoporosis caused by lymphomyeloid proliferative diseases, or to bone
- 25 resorption in a variety of diseases including osteoporosis, periodontal disease and rheumatoid arthritis. The IL1/IL1RI pathway has furthermore been implicated in atheromatosis, in coronary heart diseases, in some forms of acute renal failure, in asthma and in nasal polyposis, and in a variety of disorders in humans.

- 30 Moreover, the application of IL1RI inhibition applies in all *in vitro* and *in vivo* experimental models for the study of the above-mentioned diseases.

Another aspect of the invention relates to the use of an exon-bridging antisense oligomer according to the present invention as a medicament.

- Another aspect of the present invention relates to the use of an exon-bridging antisense oligomer according to the present invention for the production of a medicament for the treatment of any one of the diseases mentioned above.

Brief description of the figures

- The following Examples, not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying Figures, incorporated herein by reference, in which:

Figure 1: Passage of different base-length oligonucleotide probes (10, 20 and 30-mer poly A strands) through intact chondrocyte. Upper panel: Ability of fluorescent probes to enter the cytoplasm. Ordinate: mean fluorescence intensities of the cells as measured by FACS. Abscis: incubation time of the cells with the probes; The results show that probes shorter than 30 bases freely enter chondrocytes at 37°C; Lower panel: Remnant Fluorescence upon repeated washing at 37°C. Ordinate: mean fluorescence intensities of the cells as measured by FACS. Abscis: number of cell washes. From the lower panel it can be deduced that free probes were completely washed away by two washings at 37°C.

Figure 2: Annealing of FITC-labeled antisense DNA probes (FITC-probes) to mRNA in intact chondrocytes in function of exposure time. Ordinate: mean fluorescence intensity of the cells after incubation with the FITC-probes as measured by FACS. Abscis: incubation time (hours) of the cells with the FITC probes. A two-hour exposure period to the probes was enough to ensure maximal annealing to strands of specific mRNA, as shown with an aggrecan mRNA-specific exon-spanning antisense DNA probe in phenotypically stable chondrocytes.

Figure 3: Chondrocyte populations obtained from 3 different donors incubated with 0 (= control, polyA probe), 1, 2, 3 or 4 exon-bridging FITC-probes directed to aggrecan. Dots represent mean values of triplicate experiments. Ordinate: Chondrocyte MFI; Abscissa: number of probes used. The MFI values of the 3 chondrocyte populations linearly increase with the number of aggrecan mRNA directed probes used.

Figure 4: Example of an exon-bridging antisense oligonucleotide (5'-AAGATGAATTTCTTACCACGCA-3') (SEQ ID NO: 384) complementary to the sequence bridging exons 2 and 3 in the mature mRNA of the IL1R1 gene.

Figure 5: Illustration of exon-bridging probes as compared to exon-flanking probes.

EXAMPLES

Methodology

Isolation of chondrocytes

Human articular chondrocytes were isolated from articular cartilage obtained at autopsy within 24 hours post mortem. Knee joints showing focal OA lesions were used to obtain visually intact cartilage and OA cartilage. The cartilage tissue was sampled from the femur condyles, diced in small fragments and digested in a spinner bottle with a series of enzymatic solutions in Dulbecco's modified Eagle's medium (DMEM; GIBCO BRL, Grand Island, NY) with 0.002M/ml L-glutamine and antibiotics and antimycotics (GIBCO BRL) (9,10). Cartilage was first treated with 0.25% (w/v) of sheep testes hyaluronidase (Sigma, St. Louis, MO, USA) for 120 min and 0.25% of Pronase (Streptomyces griseus Pronase E; Sigma) for 90 min at 37°C. After an overnight period in DMEM supplemented with 10% foetal calf serum (FCS, GIBCO BRL), a 3 to 6 hours' incubation with 0.25% collagenase (Clostridium histolyticum; Sigma) in DMEM containing 10% FCS at 37°C resulted in the liberation of isolated cartilage cells. Depending on the condition of the tissue,

50-150×10⁶ chondrocytes could be obtained from femoral condyles of one individual and over 95% of the cells were viable (Trypan Blue exclusion test) after isolation.

5 Culture of chondrocytes in alginate gel

Chondrocyte cultures in alginate beads were prepared as described elsewhere (Guo. et al., 1989, *Conn Tiss Res* 9: 277-97) with some modifications. Chondrocytes suspended in 1 vol. double-concentrated Hanks' Balanced Salts Solution without calcium and magnesium (HBSS; Gibco) were carefully mixed with
10 an equal volume of 4% alginate (low-viscosity alginate from *Macrocystis pyrifera*; Sigma) in HBSS, autoclaved for 15 min. The final cell concentration was 5 x 10⁶ chondrocytes per ml in 2% alginate. The chondrocyte/alginate suspension was then slowly dripped through a 23-gauge needle into a 102 mM calcium chloride solution. The beads were allowed to polymerize for 10 min. at room temperature.
15 The calcium chloride was then removed, the beads were washed three times with 0.15 M sodium chloride and finally maintained in a 6-well plate in 4 ml of Dulbecco's modified Eagle's medium (DMEM; GIBCO BRL, Grand Island, NY) with 10% fetal calf serum (FCS, GIBCO BRL) and 50 µg ascorbate per ml in an incubator at 37°C under 5% CO₂. The chondrocyte cultures consisted of 1 x 10⁶
20 cells per culture. The nutrient medium was replaced twice weekly for 7-14 days.

Flow cytometry detection

Preparation of chondrocytes for flow cytometry (12): After the respective culture periods, the medium of the cultures was aspirated and the alginate beads were
25 washed and dissolved by incubation for 10 min. with 3 ml of 55 mM tri-sodium citrate dihydrate pH 6.8, 0.15 M NaCl at 25 °C. The resulting suspension was centrifuged at 1500 rpm for 10 min. to separate cells with their cell-associated matrix (CAM) from the constituents of the interterritorial matrix. Aggrecan in the CAM were tested directly after incubation with the appropriate antibody for 30 min in
30 the dark at 4°C. 20µl of 50µg/ml antibody were used to react with 2x10⁵ cells resuspended in 100µl PBS.

Antibodies used for flow cytometry: Mouse anti-human chondrocyte-specific aggrecan monoclonal antibody (mAb) (clone 4D11-2A9, Biosource Europe, Nivelles, Belgium; subclass: IgG₁) was shown to react specifically with the G1-domain of the invariable hyaluronan-binding region of the human aggrecan protein core molecule, and was used to detect the aggrecan in the chondrocyte CAM. The anti-aggrecan mAb was conjugated with Phycoerythrin (PE, Sigma-Aldrich) as described (Kronick et al., 1983, *Clin Chem* 29: 1582-6). The conjugated mAb was used in a direct immunofluorescent staining protocol for flow cytometry. Mouse anti-human mAb (subclass: IgG₁) against IL1RI were obtained from R&D systems (Abingdon, United Kingdom; clone 35730.111) and labelled with FITC using a standard protocol (Wood BT et al, 1965, *J Immunol* 95: 225-9.). Appropriate FITC- and PE-labeled isotype matched mouse IgG₁ were used as negative controls.

Flow cytometric analysis: Stained cells were analysed on a flow cytometer (FACSort, Becton Dickinson, San Jose, CA, USA) with CELLQuest software. From each sample, 15,000 events were analysed. Cells were gated on forward and side scatter to exclude dead cells, debris and aggregates. Propidium iodide was additionally used to exclude dead cells when CAM aggrecan was analysed (Wang L et al., 2001, *Osteoarthritis Cartil.* 9:73-84). The mean fluorescence intensity (MFI) of the positive cell population, which is due to the binding of the conjugated antibodies to the specific antigen, was used to quantify the presence of aggrecan in the CAM or to assess the expression of IL1RI on the plasma membrane. MFI values were obtained by subtraction of the MFI of the negative control population from the MFI of the positive stained population. For comparison between experiments Quantum Simply Cellular Microbead Kit (Sigma) was used to calibrate the fluorescence scale of the flow cytometer (Wang L et al., 2001, *Osteoarthritis Cartil.* 9: 454-62). The microbeads were stained and processed in parallel with the cell samples using the same amount of FITC-labeled antibodies and incubation time. The fluorescence scale of the cytometer was adapted before every experiment in order to keep identical MFIs for the four peaks of the calibration beads. The MFI of cell samples was then analysed without changing any

instrument settings. The reproducibility and reliability of whole procedure has been demonstrated previously (Wang L et al., 2001, *Osteoarthritis Cartil.* 9:454-62).

Probes

5 The following probes were used:

negative control probes:

probe 1: PolyA 5'FITC-aaa.aaa.aaa.aaa.aaa-3' (SEQ ID NO: 1)

specific probes:

probe 2: aggrecan (antisense) 5'FITC-cacgatgcctttcac-3' (SEQ ID NO: 2)

10 probe 3: aggrecan (antisense) 5'FITC-aaagacctcaccctc-3' (SEQ ID NO: 3)

probe 4: aggrecan (antisense) 5'FITC-ggtatctgacggctc-3' (SEQ ID NO: 4)

probe 5: aggrecan (antisense) 5'FITC-ggcattgtgtgac-3' (SEQ ID NO: 5)

probe 6: IL1RI (antisense) 5'-gaattccttaccacg-3' (SEQ ID NO: 6)

probe 7: IL1RI (antisense) 5'-gatgaattccttaccacgca-3' (SEQ ID NO: 7)

15 probe 8: IL1RI (antisense) 5'-taagatgaattccttaccacgcaa-3' (SEQ ID NO:8)

Example 1: determination of the concentration of different factors involved in ECM production by chondrocytes.

20

Osteoarthritic (OA) cartilage is characterised by destructive processes. In order to identify the most appropriate target for inhibiting this destructive process, the expression of different factors influencing ECM production were compared in chondrocytes from healthy and degenerative tissues from the same joint (Table 1).

25 The OA chondrocytes were found to show increased catabolic activity: IL1 alpha and beta concentrations inside cells were found to be increased and so were the plasma membrane levels of the signal transmitting IL1RI. However, the IL1 levels are so dramatically increased that activity of IL1 appears to be limited by the paucity of its signalling receptor IL1RI. Numbers of IL1 ligands in osteoarthritic
30 chondrocytes were observed to overpower the presence of their receptors with a factor 20-30.

Increased activity of the IGF-1/IGF1R growth factor pathway illustrates a cellular attempt of repair. However, significantly impaired accumulation of ECM compounds (aggrecan (AGGR), type II collagen (COLII), fibronectin (FNECT) are indicative of the degradation in the diseased OA cartilage tissue which will ultimately lead to severe disabling articular pathology. The IL1RII decoy receptor levels, which were found to be decreased, are apparently unable to control the increased activity of the auto/paracrine IL1/IL1RI pathway in OA chondrocytes.

Thus, in disease conditions such as osteoarthritis even a 50% or more drop of the IL1 concentrations in the extracellular environment would not make any difference as the activity of the IL1/IL1R pathway is regulated by a critical number of specific IL1 plasma membrane receptors. Based hereon it is concluded that inhibition of IL1R is the most appropriate target for inhibiting the excessive ECM destruction in OA and similar diseases.

Table 1: Homeostasis of the ECM by chondrocytes from normal and osteo- arthritic cartilage

	Normal mean \pm 1SD	Osteo- arthritic mean \pm 1SD	Difference	p-value
IL1 α	21.50 \pm 9.81	24.50 \pm 9.93	+14 %	0.0013
IL1 β	38.70 \pm 0.80	51.70 \pm 23.80	+34 %	0.0107
IL1RI	0.86 \pm 0.48	1.61 \pm 0.94	+87 %	0.0093
IL1RII	2.33 \pm 0.83	1.66 \pm 0.58	-28 %	0.0154
IGF1R	1.95 \pm 1.18	3.23 \pm 2.16	+66 %	0.0038
IGF-1	41.30 \pm 32.30	57.10 \pm 42.40	+38 %	0.0099
COLII	4.80 \pm 2.79	3.34 \pm 2.47	-30 %	0.0141
AGGR	15.50 \pm 9.13	9.50 \pm 5.89	-39 %	0.0461
FNECT	324.50 \pm 189.9	245.30 \pm 151.6	-24 %	0.0062

Example 2: Feasibility of using the exon-bridging probes.

The *in vitro* modulation of aggrecan accumulation in the cell-associated matrix (CAM) of human chondrocytes obtained from normal and osteoarthritic (OA) fibrillated articular cartilage was compared in the presence or absence of exon-bridging antisense oligomers targeting IL1RI expression.

In order to determine the requirements of the oligonucleotide probes for use in living cells, the physical factors, which influence cell-membrane permeability of probes were first evaluated. Human articular chondrocytes were obtained from three donors and the ability of 10-, 20- and 30-oligomer FITC-polyA probes, to enter the cytoplasm was tested. The same probes were used to find out if unbound FITC-probes could be washed out from the cells. Chondrocytes were isolated from alginate beads after 1 week of culture. 20 µl of 0.03mM of the probes in phosphate buffered saline (PBS) were added to 1.0 ml of DMEM containing 1.0×10^5 intact chondrocytes. To measure the optimum time for the probes to reach an equilibrium between the intra- and extracellular domains, the cells were kept in the dark at 37°C and every hour 300 µl of the cell suspension was analysed by flow cytometry.

From these experiments it appeared that probes shorter than 30 bases freely entered, and were washed away from chondrocytes at 37°C, in case they did not find their mRNA target (Figure 1).

Furthermore, time course experiments indicated that an incubation of two hours is sufficient for the probes to reach the highest intracellular concentration and to anneal optimally with the target mRNA. The results obtained after incubating phenotypically stable chondrocytes with an FITC-labelled aggrecan mRNA-specific exon-bridging antisense DNA probe (5'FITC-cacgatgccttcac-3' - SEQ ID NO : 2) are provided in Figure 2; location of the aggrecan probe in the mRNA sequence of human aggrecan 1 isoform 2 precursor (Genbank accession number 013227) : 508-522.

To find out the optimal washout procedure for uncombined or negative control poly A probes, chondrocytes were incubated with the probes for two hours and were subsequently centrifuged up to 4 times at 1,500 rpm, during 10 minutes at 37°. The residual fluorescence intensity of the stained cells was then assayed by flow cytometry.

The poly A control probes were not able to stain the target cells as they did not combine with RNA or genomic DNA. Probes directed to chondrocyte-specific mRNA, i.e. specifically directed against aggrecan, on the other hand annealed with their targets and allowed the targetted mRNA to be detected by flow cytometry. The use of multiple probes linearly increased the mean fluorescence intensity of the stained cell population (Figure 3).

15 **Example 3: design of IL1RI exon-bridging antisense oligonucleotides**

Table 2 demonstrates parts of the hIL1RI cDNA sequence which can be used for the design of exon-bridging oligonucleotides and the corresponding antisense sequence.

20

Table 2a : hIL1RI exon-bridging sequences

exon	SEQ ID NO	location in Genbank Accession NM_000877
0-1 5'-ctccaagaagaat-atgaaagtgttac-3'	9	70-95
1-2 5'-ttctctggaggctg-ataaatgcaagg-3'	10	130-155
2-3 5'-ttgcgtggtaag-aaattcatcttact-3'	11	367-392
3-4 5'-acagtgggtataag-gattgcaaacctc-3'	12	556-581
4-5 5'-atttattactctag-aggaaaacaaac-3'	13	724-749
5-6 5'-ggaagtagacttgg-gatcccagatac-3'	14	790-815
6-7 5'-agactattacag-tgtggaaaatcctg-3'	15	910-935

7-8	5'-gttaatatatccag-tcactaatttcc-3'	16	1060-1085
8-9	5'-tctcccaataaaaag-cttcagatggaa-3'	17	1204-1229
9-10	5'-ctacgttggggaag-acattgttgagg-3'	18	1372-1397

Table 2b: Exon-bridging antisense sequences of hIL1RI.

exon	Exon-bridging antisense	SEQ ID
0-1	5'-gtaacactttcat-attcttcttggag-3'	19
1-2	5'-ccttgcatTTat-cagcctccagagaa-3'	385
2-3	5'-agtaagatgaattt-cttaccacgcaa-3'	386
3-4	5'-gaggtttgcaatc-cttataccactgt-3'	387
4-5	5'-gtttgttttcct-ctagagtaataaat-3'	388
5-6	5'-gtatctgggatc-ccaagtctacttcc-3'	389
6-7	5'-caggattttccaca-ctgtaatagtct-3'	390
7-8	5'-ggaaatttagtga-ctggatatattaac-3'	391
8-9	5'-ttccatctgaag-cttttattgggaga-3'	392
9-10	5'-cctcaacaatgt-cttccccaacgtag-3'	393

- 5 Based on the sequences presented in table 4b, exon-bridging oligonucleotides for hIL1RI are designed with a length from 15 to 22 bases. These oligonucleotides have at least 4 nucleotides and at most 11 nucleotides at either 3' or 5' sequences adjacent to the exon-exon boundary between two exons. These oligonucleotides are presented in Table 3. GC content, Tm. For a few probes the similarity with
- 10 other genes are indicated.

As shown in example 4, exon-bridging oligonucleotides which have more than 11 nucleotides at one or both ends of the exon-exon boundary [20 mer en 24 mer], and/or which have a length of more than 22 nucleotides [24 mer], still can inhibit

15 hIL1RI expression.

Example 4: IL1RI antisense inhibition in chondrocytes.

Phenotypically stable human articular cartilage cells were obtained from normal and OA cartilage of the same knee showing focal OA. The cells were cultured in
5 alginate beads over 1 week, as described in example 1 to re-establish the intracellular cytokine and growth factors levels, to re-express the respective plasma membrane receptors and to reach equilibrium in accumulated cell-associated matrix (CAM) compounds. Following liberation of the cells from the alginate beads, the levels of CAM aggrecan were assayed using flow cytometry as
10 described in example 2.

When compared with cells obtained from normal cartilage tissues, the accumulation of aggrecan in the CAM was significantly reduced in the chondrocytes obtained from pathological tissue. This repression of CAM aggrecan
15 was due to an increased activity of the catabolic IL1/IL1RI pathway in these cells, as illustrated an increased expression of IL1 and IL1RI on the plasma membrane of the OA chondrocytes, when compared with the cells obtained from normal tissues (see example 1 in this document). The chondrocytes were exposed to an IL1RI mRNA targeting exon bridging antisense oligonucleotide. A 15mer (probe 6;
20 SEQ ID NO:6), 20mer (probe 7; SEQ ID NO 7) and 24 mer (probe 8, SEQ ID NO: 8) oligonucleotide was used as antisense oligonucleotide against IL1RI, all three bridging coding exons 2 and 3. All oligonucleotides had phosphorothioate modifications.

25 The efficacy of these oligonucleotide to silence IL1RI expression was tested on OA chondrocytes, as these cells were shown to express higher levels of this IL1 receptor (Table 4).

Table 4: Effect of IL1RI exon-bridging antisense oligonucleotides on IL1RI expression.

		15 mer [SEQ ID NO:6]			
		0 nM	1 nM	10 nM	100 nM
MFI	for	0.42 ± 0.04	0.48 ± 0.10	0.45 ± 0.15	0.14 ± 0.09
IL1RI					
p-value			> 0.10	> 0.10	< 0.10

		20 mer [SEQ ID NO:7]			
		0 nM	1 nM	10 nM	100 nM
MFI	for	0.42 ± 0.04	0.28 ± 0.05	0.16 ± 0.10	0.12 ± 0.04
IL1RI					
p-value			< 0.10	< 0.10	< 0.10

- 5 The chondrocytes in this experiment were obtained from a 64-year-old female. Results are expressed as Mean Fluorescence Intensity (MFI) for IL1RI of the cell population following staining of the cells with the FITC-labelled anti human IL1RI mAb, and after exposure to different concentrations (nM) of the antisense oligonucleotide. Experiments were performed in triplicate. Mean and 1SD are given. Statistical analysis was performed using the Student's T-Test.

The 20 mer antisense oligonucleotide [SEQ ID NO : 7] efficiently suppressed the expression of plasma membrane IL1RI. The 15mer [SEQ ID NO: 6] IL1RI antisense oligonucleotide showed less effects. Although the 20 in Table 4 is more effective at higher concentrations, 1 nM concentrations of the probe inhibited plasma membrane IL1RI expression with 33.4%.

20 **Example 5 : Reversal of repression of the accumulation of aggrecan in the CAM of the OA chondrocytes.**

Aggrecan accumulation was assayed after administration of the 20mer IL1RI antisense oligonucleotide [SEQ ID NO: 7] on OA chondrocytes obtained from 3 different patients (Table 5). For comparison, normal chondrocytes were obtained from one of these donors.

The administration of this antisense oligonucleotide had no effect on the aggrecan accumulation of chondrocytes from normal cartilage. However, repression of the accumulation of aggrecan in the CAM of the osteoarthritic chondrocytes was completely reversed when the 20 mer antisense oligonucleotide was added to these cells in culture. The effect was significant and dose-related when the oligonucleotide was added to a final concentration in the nutrient medium ranging from 1.0 to 100.0 nM.

Table 5: Effect of IL1RI antisense oligonucleotides on CAM aggrecan synthesis of chondrocytes

Donor F64 OA	0 nM	1 nM	10 nM	100 nM
MFI for aggrecan	100 ± 0.0	128.9 ± 6.8	128.2 ± 3.1	142.1 ± 2.1
p-value		< 0.10	< 0.10	< 0.10
Donor M69 OA	0 nM	1 nM	10 nM	100 nM
MFI for aggrecan	100 ± 0.0	121.1 ± 19.8	127.8 ± 18.5	133.0 ± 17.5
p-value		< 0.10	< 0.10	< 0.10
Donor M60 OA	0 nM	1 nM	10 nM	100 nM
MFI for aggrecan	100 ± 0.0	117.6 ± 4.5	120.8 ± 4.5	139.4 ± 5.0
p-value		< 0.10	< 0.10	< 0.10
Donor M60 - NO	0 nM	1 nM	10 nM	100 nM
MFI for aggrecan	100 ± 0.0	97.4 ± 3.2	98.3 ± 5.2	102.1 ± 3.1
p-value		> 0.10	> 0.10	> 0.10

Experiments performed on the chondrocytes obtained from 3 different donors. Sex (F/M) and donor age are given. Results expressed as Mean Fluorescence Intensity (MFI) of the cell population after exposure to different concentrations (1-100 nM) of the antisense oligonucleotide. Control values were normalised to 100%. Experiments were performed in triplicate. Mean and 1SD are given. Statistics : Student's t-test.

Example 6 : Reversal of repression of the accumulation of aggrecan in the CAM of OA chondrocytes.

Further experiments were performed to evaluate the effects of 9 different exon-bridging probes corresponding to the 9 exon-bridging sequences in the IL1R1 mRNA. A comparison was made of the effects of exon-bridging and non-exon-bridging probes, i.e. antisense probes to sequences flanking the 5'-end of the corresponding exon bridge ('exon-flanking' probes, Figure 5). Moreover, a comparison was made with the effect of a non-exon bridging probe of the prior art, i.e. ISIS 8807 (described in US Patent No. 5,856,099).

The sequence of the oligomers used in this experiment are provided in Table 6.

1 nM concentrations were used. All tests were done in triplicate. The accumulation of aggrecan in the CAM of the chondrocytes in culture (MFI values obtained by flow cytometry) was used as a variable. The ISIS 8807 probe was used in comparison at a 1 nM concentration.

Table 6 : probes used

EBR	'flanking' probes	SEQ-ID/probe		exon-bridging probes	SEQ-ID/probe
01-02	5-ttattttttcttcacgttcc-3	29	vs.	5'-ttgcatttat-cagcctccag-3'	20
02-03	5-attttaattctgaggcagta-3	30	vs.	5'-agatgaattt-cttaccacgc-3'	21
03-04	5-tatattgtcaagaagtagag-3	31	vs.	5'-gtttgcaatc-cttataccac-3'	22
04-05	5-caatcacaggccttgtgggt-3	32	vs.	5'-ttgttttcct-ctagagtaat-3'	23
05-06	5-tgacattacagatcaattgt-3	33	vs.	5'-atctgggatc-ccaagtctac-3'	24
06-07	5-ctccttcttttgtttgcagg-3	34	vs.	5'-atttccaca-ctgtaatagt-3'	25
07-08	5-taccaatcatgtgcttctgg-3	35	vs.	5'-aaattagtga-ctggatatat-3'	26
08-09	5-tatatgcgtcataggtcttt-3	36	vs.	5'-ccatctgaag-cttttattgg-3'	27
09-10	5-ttacgttttcattaatgacc-3	37	vs.	5'-tcaacaatgt-cttccccaac-3'	28

ISIS 8807: 5-tgtgtccaatcggtggc (directed against 3'UTR) (SEQ ID NO:38)

In order to obtain the percentage increases in MFI (cell-bound aggrecan) due to the effects of the different antisense sequences, the values for the control cultures were normalized to 100. A number of exon-bridging sequences were found to inhibit IL1R1 similarly or more significantly than their non-exon bridging counterparts. The aggrecan synthesis of the cells was significantly increased for both the oligomers corresponding to the exon 02-03 and 05-06. More particularly, from these experiments it could be deduced that the exon-bridging sequences eb02-03 (SEQ ID 21) and eb05-06 (SEQ ID 24) are particularly suited for IL1R1 inhibition.

The ISIS 8807 antisense sequence was not effective at the concentrations used.

Table 3: Potential exon-bridging oligomers

SEQ ID NOs are listed after the sequences in square brackets

5 A. EXON 01→02 exon-bridging oligomers

5'-CCTTGCATTTAT-CAGCCTCCAGAGAA-3' [76]

15mer exon-spanning probes

10 position 133-147; 134-148; 135-149; 136-150; 137-151; 138-152; 139-153; 140-154

	probe	GC content	Tm
	5'-TTAT-CAGCCTCCAGA-3' [39]	07/15=46.7%	44
15	5'-TTTAT-CAGCCTCCAG-3' [40]	07/15=46.7%	44
	5'-ATTTAT-CAGCCTCCA-3' [41]	06/15=40.0%	42
	5'-CATTTAT-CAGCCTCC-3' [42]	07/15=46.7%	44
	5'-GCATTTAT-CAGCCTC-3' [43]	07/15=46.7%	44
	5'-TGCATTTAT-CAGCCT-3' [44]	06/15=40.0%	42
20	5'-TTGCATTTAT-CAGCC-3' [45]	06/15=40.0%	42
	5'-CTTGCATTTAT-CAGC-3' [46]	06/15=40.0%	42

16 mer exon-spanning probes

25 position 133-148; 134-149; 135-150; 136-151; 137-152; 138-153; 139-154

	probe	GC content	Tm
	5'-TTTAT-CAGCCTCCAGA-3' [47]	07/16=43.8%	46
30	5'-ATTTAT-CAGCCTCCAG-3' [48]	07/16=43.8%	46
	5'-CATTTAT-CAGCCTCCA-3' [49]	07/16=43.8%	46
	5'-GCATTTAT-CAGCCTCC-3' [50]	08/16=50.0%	48
	5'-TGCATTTAT-CAGCCTC-3' [51]	07/16=43.8%	46
	5'-TTGCATTTAT-CAGCCT-3' [52]	06/16=37.5%	44
35	5'-CTTGCATTTAT-CAGCC-3' [53]	07/16=43.8%	46

17 mer exon-spanning probes

position 133-149; 134-150; 135-151; 136-152; 137-153; 138-154

	probe	GC content	Tm
	5'-ATTTAT-CAGCCTCCAGA-3' [54]	07/17=42.2%	48
	5'-CATTTAT-CAGCCTCCAG-3' [55]	08/17=47.1%	50
	5'-GCATTTAT-CAGCCTCCA-3' [56]	08/17=47.1%	50
45	5'-TGCATTTAT-CAGCCTCC-3' [57]	08/17=47.1%	50
	5'-TTGCATTTAT-CAGCCTC-3' [58]	07/17=42.2%	48
	5'-CTTGCATTTAT-CAGCCT-3' [59]	07/17=42.2%	48

Table 3: Potential exon-bridging oligomers (continued)

18 mer exon-spanning probes			
position 133-150; 134-151; 135-152; 136-153; 137-154			
5	-----		
	probe	GC content	Tm
	5'-CATTTAT-CAGCCTCCAGA-3' [60]	08/18=44.4%	52
	5'-GCATTTAT-CAGCCTCCAG-3' [61]	09/18=50.0%	54
	5'-TGCATTTAT-CAGCCTCCA-3' [62]	08/18=44.4%	52
10	5'-TTGCATTTAT-CAGCCTCC-3' [63]	08/18=44.4%	52
	5'-CTTGCATTTAT-CAGCCTC-3' [64]	08/18=44.4%	52
19 mer exon-spanning probes			
position 133-151; 134-152; 135-153; 136-154			
15	-----		
	probe	GC content	Tm
	5'-GCATTTAT-CAGCCTCCAGA-3' [65]	09/19=47.4%	56
	5'-TGCATTTAT-CAGCCTCCAG-3' [66]	09/19=47.4%	56
20	5'-TTGCATTTAT-CAGCCTCCA-3' [67]	08/19=42.1%	54
	5'-CTTGCATTTAT-CAGCCTCC-3' [68]	09/19=47.4%	56
20 mer exon-spanning probes			
position 133-152; 134-153; 135-154			
25	-----		
	probe	GC content	Tm
	5'-TGCATTTAT-CAGCCTCCAGA-3' [69]	09/20=45.0%	58
	5'-TTGCATTTAT-CAGCCTCCAG-3' [70]	09/20=45.0%	58
30	5'-CTTGCATTTAT-CAGCCTCCA-3' [71]	09/20=45.0%	58
21 mer exon-spanning probes			
position 133-153 ; 134-154			
35	-----		
	probe	GC content	Tm
	5'-TTGCATTTAT-CAGCCTCCAGA-3' [72]	09/21=42.9%	60
	5'-CTTGCATTTAT-CAGCCTCCAG-3' [73]	10/21=47.6%	62
22 mer exon-spanning probe			
position 133-154			
40	-----		
	probe	GC content	Tm
	5'-CTTGCATTTAT-CAGCCTCCAGA-3' [74]	10/22=45.5%	64°C
25 mer exon-spanning probe			
position 131-155			
45	-----		
	probe	GC content	Tm
	5'-CCTTGCATTTAT-CAGCCTCCAGAGA-3' [75]	12/25=48.0%	74°C

Table 3: Potential exon-bridging oligomers (continued)**B. EXON 02→03 exon-bridging oligomers**

5 5'-AGTAAGATGAATTT--CTTACCACGCAA-3' [77]

15 mer exon-spanning probes

position 368-382; 369-383; 370-384; 371-385; 372-386; 373-387; 374-388; 375-389

10	probe	GC content	Tm
	5'-ATTT-CTTACCACGCA-3' [78]	06/15=40.0%	42
	5'-AATTT-CTTACCACGC-3' [79]	06/15=40.0%	42
	5'-GAATTT-CTTACCACG-3' [80]	06/15=40.0%	42
15	5'-TGAATTT-CTTACCAC-3' [81]	05/15=33.3%	40
	5'-ATGAATTT-CTTACCA-3' [82]	04/15=26.7%	38
	5'-GATGAATTT-CTTACC-3' [83]	05/15=33.3%	40
	5'-AGATGAATTT-CTTAC-3' [84]	04/15=26.7%	38
20	5'-AAGATGAATTT-CTTA-3' [85]	03/15=20.0%	36

16 mer exon-spanning probes

position 368-383; 369-384; 370-385; 371-386; 372-387; 373-388; 374-389

25	probe	GC content	Tm
	5'-AATTT-CTTACCACGCA-3' [86]	06/16=37.5%	44
	5'-GAATTT-CTTACCACGC-3' [87]	07/16=43.8%	46
	5'-TGAATTT-CTTACCACG-3' [88]	06/16=37.5%	44
30	5'-ATGAATTT-CTTACCAC-3' [89]	05/16=31.5%	42
	5'-GATGAATTT-CTTACCA-3' [90]	05/16=31.5%	42
	5'-AGATGAATTT-CTTACC-3' [91]	05/16=31.5%	42
	5'-AAGATGAATTT-CTTAC-3' [92]	04/16=25.0%	40

35 17 mer exon-spanning probes

position 368-384; 369-385; 370-386; 371-387; 372-388; 373-389

40	probe	GC content	Tm
	5'-GAATTT-CTTACCACGCA-3' [93]	07/17=41.2%	48
	5'-TGAATTT-CTTACCACGC-3' [94]	07/17=41.2%	48
	5'-ATGAATTT-CTTACCACG-3' [95]	06/17=35.3%	46
	5'-GATGAATTT-CTTACCAC-3' [96]	06/17=35.3%	46
	5'-AGATGAATTT-CTTACCA-3' [97]	05/17=29.4%	44
45	5'-AAGATGAATTT-CTTACC-3' [98]	05/17=29.4%	44

Table 3: Potential exon-bridging oligomers (continued)

18 mer exon-spanning probes			
position 368-385; 369-386; 370-387; 371-388; 372-389			
5	-----		
	probe	GC content	Tm
	5'-TGAATTT-CTTACCACGCA-3' [99]	07/18=38.9%	50
	5'-ATGAATTT-CTTACCACGC-3' [100]	07/18=38.9%	50
	5'-GATGAATTT-CTTACCACG-3' [101]	07/18=38.9%	50
10	5'-AGATGAATTT-CTTACCAC-3' [102]	06/18=35.3%	48
	5'-AAGATGAATTT-CTTACCA-3' [103]	05/18=27.8%	46
19 mer exon-spanning probes			
position 368-386; 369-387; 370-388; 371-389			
15	-----		
	probe	GC content	Tm
	5'-ATGAATTT-CTTACCACGCA-3' [104]	07/19=36.8%	52
	5'-GATGAATTT-CTTACCACGC-3' [105]	08/19=42.1%	54
	5'-AGATGAATTT-CTTACCACG-3' [106]	07/19=36.8%	52
20	5'-AAGATGAATTT-CTTACCAC-3' [107]	06/19=31.6%	50
20 mer exon-spanning probes			
position 368-387; 369-388; 370-389			
25	-----		
	probe	GC content	Tm
	5'-GATGAATTT-CTTACCACGCA-3' [108]	08/20=40.0%	56
	5'-AGATGAATTT-CTTACCACGC-3' [109]	08/20=40.0%	56
30	5'-AAGATGAATTT-CTTACCACG-3' [110]	07/20=35.0%	54
21 mer exon-spanning probes			
position 368-388; 369-389			

	probe	GC content	Tm
35	5'-AGATGAATTT-CTTACCACGCA-3' [111]	08/21=38.1%	58
	5'-AAGATGAATTT-CTTACCACGC-3' [112]	08/21=38.1%	58
22 mer exon-spanning probes			
position 368-389			
40	-----		
	probe	GC content	Tm
	5'-AAGATGAATTT-CTTACCACGCA-3' [113]	08/22=36.4%	60
25 mer exon-spanning probe			
position 368-392			
45	-----		
	probe	GC content	Tm
	5'-AGTAAGATGAATTT-CTTACCACGCAA-3' [114]	09/25=36.0%	68

Table 3: Potential exon-bridging oligomers (continued)C. EXON 03-04 exon-bridging oligomers

5	5'-GAGGTTTGCAATC-CTTATAACCACTGT-3' [115]		
	15 mer exon-spanning probes		
10	position 558-572; 559-573; 560-574; 561-575; 562-576; 563-577; 564-578; 565-579		

	probe	GC content	Tm
	5'-AATC-CTTATAACCACT-3' [116]	05/15=33.3%	40
	5'-CAATC-CTTATAACCACT-3' [117]	06/15=40.0%	42
15	5'-GCAATC-CTTATAACCA-3' [118]	06/15=40.0%	42
	5'-TGCAATC-CTTATAACCA-3' [119]	06/15=40.0%	42
	5'-TTGCAATC-CTTATAAC-3' [120]	05/15=33.3%	40
	5'-TTTGCAATC-CTTATA-3' [121]	04/15=26.7%	38
	5'-GTTTGCAATC-CTTAT-3' [122]	05/15=33.3%	40
20	5'-GGTTTGCAATC-CTTA-3' [123]	06/15=40.0%	42
	16 mer exon-spanning probes		
	position 558-573; 559-574; 560-575; 561-576; 562-577; 563-578; 564-579		
25	-----		
	probe	GC content	Tm
	5'-CAATC-CTTATAACCACT-3' [124]	05/16=33.3%	42
	5'-GCAATC-CTTATAACCACT-3' [125]	06/16=40.0%	44
	5'-TGCAATC-CTTATAACCA-3' [126]	06/16=40.0%	44
30	5'-TTGCAATC-CTTATAACCA-3' [127]	06/16=40.0%	44
	5'-TTTGCAATC-CTTATAAC-3' [128]	05/16=33.3%	42
	5'-GTTTGCAATC-CTTATA-3' [129]	04/16=26.7%	40
	5'-GGTTTGCAATC-CTTAT-3' [130]	05/16=33.3%	42
35	17 mer exon-spanning probes		
	position 558-574; 559-575; 560-576; 561-577; 562-578; 563-579		

	probe	GC content	Tm
40	5'-GCAATC-CTTATAACCACT-3' [131]	07/17=42.2%	48
	5'-TGCAATC-CTTATAACCACT-3' [132]	07/17=42.2%	48
	5'-TGCAATC-CTTATAACCA-3' [133]	06/17=35.3%	46
	5'-TTTGCAATC-CTTATAACCA-3' [134]	06/17=35.3%	46
	5'-GTTTGCAATC-CTTATAAC-3' [135]	06/17=35.3%	46
45	5'-GGTTTGCAATC-CTTATA-3' [136]	06/17=35.3%	46

Table 3: Potential exon-bridging oligomers (continued)

18 mer exon-spanning probes			
position 558-575; 559-576; 560-577; 561-578; 562-579			
5	-----		
	probe	GC content	Tm
	5'-TGCAATC-CTTATAACCACT-3' [137]	07/18=42.2%	50
	5'-TTGCAATC-CTTATAACCAC-3' [138]	07/18=42.2%	50
	5'-TTTGCAATC-CTTATAACCA-3' [139]	06/18=35.3%	48
10	5'-GTTTGCAATC-CTTATAACC-3' [140]	06/18=35.3%	48
	5'-GGTTTGCAATC-CTTATAC-3' [141]	06/18=35.3%	48
19 mer exon-spanning probes			
position 558-576; 559-577; 560-578; 561-579			
15	-----		
	probe	GC content	Tm
	5'-TTGCAATC-CTTATAACCACT-3' [142]	07/19=36.8%	52
	5'-TTTGCAATC-CTTATAACCAC-3' [143]	07/19=36.8%	52
	5'-GTTTGCAATC-CTTATAACCA-3' [144]	07/19=36.8%	52
20	5'-GGTTTGCAATC-CTTATAACC-3' [145]	08/19=42.1%	54
20 mer exon-spanning probes			
position 558-577; 559-578; 560-579			
25	-----		
	probe	GC content	Tm
	5'-TTTGCAATC-CTTATAACCACT-3' [146]	07/20=35.0%	54
	5'-GTTTGCAATC-CTTATAACCAC-3' [147]	08/20=40.0%	56
	5'-GGTTTGCAATC-CTTATAACCA-3' [148]	08/20=40.0%	56
30	21 mer exon-spanning probes		
position 558-578; 559-579			

	probe	GC content	Tm
	5'-GTTTGCAATC-CTTATAACCACT-3' [149]	08/21=38.1%	58°C 6
35	5'-GGTTTGCAATC-CTTATAACCAC-3' [150]	09/21=42.9%	60°C 9
22 mer exon-spanning probes			
position 558-579			
40	-----		
	probe	GC content	Tm
	5'-GGTTTGCAATC-CTTATAACCACT-3' [151]	09/22=40.9%	62°C 10

Table 3: Potential exon-bridging oligomers (continued)

22 mer exon-spanning probes
position 559-581

5

probe	GC content	Tm
5'-GAGGTTTGCAATC-CTTATACCACTG-3' [152]	11/25=44.0%	72°C

D. EXON 04→05 exon-bridging oligomers

5'-GTTTGTTTTCCTC-TAGAGTAATAAAT-3' [153]

15 mer exon-spanning probes
position 727-741; 728-742; 729-743; 730-744; 731-745; 732-746; 733-747; 734-748

15

probe	GC content	Tm
5'-TCCT-CTAGAGTAATA-3' [154]	05/15=33.3%	40
5'-TTCCT-CTAGAGTAAT-3' [155]	05/15=33.3%	40
5'-TTTCCT-CTAGAGTAA-3' [156]	05/15=33.3%	40
5'-TTTTTCCT-CTAGAGTA-3' [157]	05/15=33.3%	40
5'-GTTTTTCCT-CTAGAGT-3' [158]	06/15=40.0%	42
5'-GTTTTTCCT-CTAGAGT-3' [159]	06/15=40.0%	42
5'-TTGTTTTTCCT-CTAGA-3' [160]	05/15=33.3%	40
5'-TTTGTTTTTCCT-CTAG-3' [161]	05/15=33.3%	40

20

25

16 mer exon-spanning probes
position 727-742; 728-743; 729-744; 730-745; 731-746; 732-747; 733-748

30

probe	GC content	Tm
5'-TTCCT-CTAGAGTAATA-3' [162]	05/16=31.3%	42
5'-TTTCCT-CTAGAGTAAT-3' [163]	05/16=31.3%	42
5'-TTTCCT-CTAGAGTAA-3' [164]	05/16=31.3%	42
5'-GTTTTTCCT-CTAGAGTA-3' [165]	06/16=37.5%	44
5'-TGTTTTTCCT-CTAGAGT-3' [166]	06/16=37.5%	44
5'-TTGTTTTTCCT-CTAGAG-3' [167]	06/16=37.5%	44
5'-TTTGTTTTTCCT-CTAGA-3' [168]	05/16=31.3%	42

35

40

17 mer exon-spanning probes
position 727-743; 728-744; 729-745; 730-746; 731-747; 732-748

45

probe	GC content	Tm
5'-TTTCCT-CTAGAGTAATA-3' [169]	05/17=29.4%	44
5'-TTTTTCCT-CTAGAGTAAT-3' [170]	05/17=29.4%	44
5'-GTTTTTCCT-CTAGAGTAA-3' [171]	06/17=35.3%	46
5'-TGTTTTTCCT-CTAGAGTA-3' [172]	06/17=35.3%	46

Table 3: Potential exon-bridging oligomers (continued)

5

5'-TTGTTTTTCCT-CTAGAGT-3' [173] 06/17=35.3% 46

5'-TTTGTTCCT-CTAGAG-3' [174] 06/17=35.3% 46

18 mer exon-spanning probes

position 727-744; 728-745; 729-746; 730-747; 731-748

10

probe GC content Tm

5'-TTTTTCCT-CTAGAGTAATA-3' [175] 05/18=27.8% 46

5'-GTTTTTCCT-CTAGAGTAAT-3' [176] 06/18=33.3% 48

5'-TGTTTTTCCT-CTAGAGTAA-3' [177] 06/18=33.3% 48

5'-TTGTTTTTCCT-CTAGAGTA-3' [178] 06/18=33.3% 48

15

5'-TTTGTTCCT-CTAGAGT-3' [179] 06/18=33.3% 48

19 mer exon-spanning probes

position 727-745; 728-746; 729-747; 730-748

20

probe GC content Tm

5'-GTTTTTCCT-CTAGAGTAATA-3' [180] 06/19=31.6% 50

5'-TGTTTTTCCT-CTAGAGTAAT-3' [181] 06/19=31.6% 50

5'-TTGTTTTTCCT-CTAGAGTAA-3' [182] 06/19=31.6% 50

5'-TTTGTTCCT-CTAGAGTA-3' [183] 06/19=31.6% 50

25

20 mer exon-spanning probes

position 727-746; 728-747; 729-748

30

probe GC content Tm

5'-TGTTTTTCCT-CTAGAGTAATA-3' [184] 06/20=30.0% 52

5'-TTGTTTTTCCT-CTAGAGTAAT-3' [185] 06/20=30.0% 52

5'-TTTGTTCCT-CTAGAGTAA-3' [186] 06/20=30.0% 52

35

21 mer exon-spanning probes

position 727-747; 728-748

40

probe GC content Tm

5'-TTGTTTTTCCT-CTAGAGTAATA-3' [187] 06/21=28.6% 54

5'-TTTGTTCCT-CTAGAGTAAT-3' [188] 06/21=28.6% 54

22 mer exon-spanning probes

position 727-749

45

probe GC content Tm

5'-TTTGTTCCT-CTAGAGTAATA-3' [189] 06/22=27.3% 56° 45

NB5'-12mer

Table 3: Potential exon-bridging oligomers (continued)

25 mer exon-spanning probes

position 725-749

5	-----			
	probe	GC content	Tm	
	5'-GTTTGTTCCT-CTAGAGTAATAAA-3' [190]	07/25=28.0%	64%	

10 E. EXON 05→06 exon-bridging oligomers

5'-GTATCTGGGATC-CCAAGTCTACTTCC-3' [191]

15 mer exon-spanning probes

15 position 793-807; 794-808; 795-809; 796-810; 797-811; 798-812; 799-813; 800-814

	probe	GC content	Tm	
	5'-GATC-CCAAGTCTACT-3' [192]	07/15=46.7%	44	
20	5'-GGATC-CCAAGTCTAC-3' [193]	08/15=53.3%	46	
	5'-GGGATC-CCAAGTCTA-3' [194]	08/15=53.3%	46	
	5'-TGGGATC-CCAAGTCT-3' [195]	08/15=53.3%	46	
	5'-CTGGGATC-CCAAGTC-3' [196]	09/15=60.0%	48	
	5'-TCTGGGATC-CCAAGT-3' [197]	08/15=53.3%	46	
25	5'-ATCTGGGATC-CCAAG-3' [198]	08/15=53.3%	46	
	5'-TATCTGGGATC-CCAA-3' [199]	07/15=46.7%	44	

16 mer exon-spanning probes

30 position 793-808; 794-809; 795-810; 796-811; 797-812; 798-813; 799-814

	probe	GC content	Tm	
	5'-GGATC-CCAAGTCTACT-3' [200]	08/16=50.0%	48	
	5'-GGGATC-CCAAGTCTAC-3' [201]	09/16=56.3%	50	
35	5'-TGGGATC-CCAAGTCTA-3' [202]	08/16=50.0%	48	
	5'-CTGGGATC-CCAAGTCT-3' [203]	09/16=56.3%	50	
	5'-TCTGGGATC-CCAAGTC-3' [204]	09/16=56.3%	50	
	5'-ATCTGGGATC-CCAAGT-3' [205]	08/16=50.0%	48	
	5'-TATCTGGGATC-CCAAG-3' [206]	08/16=50.0%	48	

40

17 mer exon-spanning probes

position 793-809; 794-810; 795-811; 796-812; 797-813; 798-814

45	probe	GC content	Tm	
	5'-GGGATC-CCAAGTCTACT-3' [207]	09/17=52.9%	52	
	5'-TGGGATC-CCAAGTCTAC-3' [208]	09/17=52.9%	52	
	5'-CTGGGATC-CCAAGTCTA-3' [209]	09/17=52.9%	52	
	5'-TCTGGGATC-CCAAGTCT-3' [210]	09/17=52.9%	52	

Table 3: Potential exon-bridging oligomers (continued)

	5'-ATCTGGGATC-CCAAGTC-3' [211]	09/17=52.9%	52
	5'-TATCTGGGATC-CCAAGT-3' [212]	08/17=47.1%	50
5	18 mer exon-spanning probes position 793-810; 794-811; 795-812; 796-813; 797-814		

10	probe	GC content	Tm
	5'-TGGGATC-CCAAGTCTACT-3' [213]	09/18=50.0%	54
	5'-CTGGGATC-CCAAGTCTAC-3' [214]	10/18=55.5%	56
	5'-TCTGGGATC-CCAAGTCTA-3' [215]	09/18=50.0%	54
	5'-ATCTGGGATC-CCAAGTCT-3' [216]	09/18=50.0%	54
15	5'-TATCTGGGATC-CCAAGTC-3' [217]	09/18=50.0%	54
	19 mer exon-spanning probes position 793-811; 794-812; 795-813; 796-814		

20	probe	GC content	Tm
	5'-CTGGGATC-CCAAGTCTACT-3' [218]	10/19=52.6%	58
	5'-TCTGGGATC-CCAAGTCTAC-3' [219]	10/19=52.6%	58
	5'-ATCTGGGATC-CCAAGTCTA-3' [220]	09/19=47.4%	56
	5'-TATCTGGGATC-CCAAGTCT-3' [221]	09/19=47.4%	56
25	20 mer exon-spanning probes position 793-812; 794-813; 795-814		

	probe	GC content	Tm
30	5'-TCTGGGATC-CCAAGTCTACT-3' [222]	10/20=50.0%	60
	5'-ATCTGGGATC-CCAAGTCTAC-3' [223]	10/20=50.0%	60
	5'-TATCTGGGATC-CCAAGTCTA-3' [224]	09/20=45.0%	58
	21 mer exon-spanning probes position 793-813; 794-814		

	probe	GC content	Tm
	5'-ATCTGGGATC-CCAAGTCTACT-3' [225]	10/21=47.6%	62
	5'-TATCTGGGATC-CCAAGTCTAC-3' [226]	10/21=47.6%	62
40	22 mer exon-spanning probes position 793-814		

	probe	GC content	Tm
45	5'-TATCTGGGATC-CCAAGTCTACT-3' [227]	10/22=45.5%	64

Table 3: Potential exon-bridging oligomers (continued)

25 mer exon-spanning probes
position 791-815

5

probe	GC content	Tm
5'-GTATCTGGGATC-CCAAGTCTACTTC-3' [228]	12/25=48.0%	74

10

F. EXON 06→07 exon-bridging oligomers

5'-CAGGATTTTCCACA-CTGTAATAGTCT-3' [229]

15 mer exon-spanning probes
position 911-925; 912-926; 913-927; 914-928; 915-929; 916-930; 917-931; 918-932

15

probe	GC content	Tm
5'-CACA-CTGTAATAGTC-3' [230]	06/15=40.0%	42
5'-CCACA-CTGTAATAGT-3' [231]	06/15=40.0%	42
5'-TCCACA-CTGTAATAG-3' [232]	06/15=40.0%	42
5'-TTCCACA-CTGTAATA-3' [233]	05/15=33.0%	40
5'-TTTCCACA-CTGTAAT-3' [234]	05/15=33.3%	40
5'-TTTTCCACA-CTGTAA-3' [235]	05/15=33.3%	40
5'-ATTTTCCACA-CTGTA-3' [236]	05/15=33.3%	40
5'-GATTTTCCACA-CTGT-3' [237]	06/15=40.0%	42

20

16 mer exon-spanning probes
position 911-926; 912-927; 913-928; 914-929; 915-930; 916-931; 917-932

25

probe	GC content	Tm
5'-CCACA-CTGTAATAGTC-3' [238]	07/16=43.8%	46
5'-TCCACA-CTGTAATAGT-3' [239]	06/16=37.5%	44
5'-TTCCACA-CTGTAATAG-3' [240]	06/16=37.5%	44
5'-TTTCCACA-CTGTAATA-3' [241]	05/16=31.3%	42
5'-TTTTCCACA-CTGTAAT-3' [242]	05/16=31.3%	42
5'-ATTTTCCACA-CTGTAA-3' [243]	05/16=31.3%	42
5'-GATTTTCCACA-CTGTA-3' [244]	06/16=37.5%	44

30

17 mer exon-spanning probes
position 911-927; 912-928; 913-929; 914-930; 915-931; 916-932

35

probe	GC content	Tm
5'-TCCACA-CTGTAATAGTC-3' [245]	07/17=41.2%	48
5'-TTCCACA-CTGTAATAGT-3' [246]	06/17=35.3%	46
5'-TTTCCACA-CTGTAATAG-3' [247]	06/17=35.3%	46
5'-TTTTCCACA-CTGTAATA-3' [248]	05/17=29.4%	44

40

45

Table 3: Potential exon-bridging oligomers (continued)

	5'-ATTTTCCACA-CTGTAAT-3' [249]	05/17=29.4%	44
5	5'-GATTTTCCACA-CTGTAA-3' [250]	06/17=35.3%	46
18 mer exon-spanning probes position 911-928; 912-929; 913-930; 914-931; 915-932			

10	probe	GC content	Tm
	5'-TTCCACA-CTGTAATAGTC-3' [251]	07/18=38.9%	50
	5'-TTTCCACA-CTGTAATAGT-3' [252]	06/18=33.3%	48
	5'-TTTTCCACA-CTGTAATAG-3' [253]	06/18=33.3%	48
	5'-ATTTTCCACA-CTGTAATA-3' [254]	05/18=27.8%	46
15	5'-GATTTTCCACA-CTGTAAT-3' [255]	06/18=33.3%	48
19 mer exon-spanning probes position 911-929; 912-930; 913-931; 914-932			

20	probe	GC content	Tm
	5'-TTTCCACA-CTGTAATAGTC-3' [256]	07/19=36.8%	52
	5'-TTTTCCACA-CTGTAATAGT-3' [257]	06/19=31.6%	50
	5'-ATTTTCCACA-CTGTAATAG-3' [258]	06/19=31.6%	50
25	5'-GATTTTCCACA-CTGTAATA-3' [259]	06/19=31.6%	50
20 mer exon-spanning probes position 911-930; 912-931; 913-932			

	probe	GC content	Tm
30	5'-TTTTCCACA-CTGTAATAGTC-3' [260]	07/20=35.0%	54
	5'-ATTTTCCACA-CTGTAATAGT-3' [261]	06/20=30.0%	52
	5'-GATTTTCCACA-CTGTAATAG-3' [262]	07/20=35.0%	54
21 mer exon-spanning probes position 911-931; 912-932			

	probe	GC content	Tm
40	5'-ATTTTCCACA-CTGTAATAGTC-3' [263]	07/21=33.3%	56
	5'-GATTTTCCACA-CTGTAATAGT-3' [264]	07/21=33.3%	56
22 mer exon-spanning probes position 911-932			

	probe	GC content	Tm
45	5'-GATTTTCCACA-CTGTAATAGTC-3' [265]	08/22=40.9%	60°C 46
25 mer exon-spanning probes position 911-935			

Table 3: Potential exon-bridging oligomers (continued)

	probe	GC content	Tm
5	5'-CAGGATTTTCCACA-CTGTAATAGTC-3' [266]	10/25=40.0%	70°C
G. EXON 07→08 exon-bridging oligomers			
10	5'-GGAAATTAGTGA-CTGGATATATTAAC-3' [267]		
15 mer exon-spanning probes			
position 1063-1077; 1064-1078; 1065-1079; 1066-1080; 1067-1081; 1068-1082; 1069-1083; 1070-1084			
15	-----		
	probe	GC content	Tm
	5'-GTGA-CTGGATATATT-3' [268]	05/15=33.3%	40
	5'-AGTGA-CTGGATATAT-3' [269]	05/15=33.3%	40
	5'-TAGTGA-CTGGATATA-3' [270]	05/15=33.3%	40
20	5'-TTAGTGA-CTGGATAT-3' [271]	05/15=33.3%	40
	5'-ATTAGTGA-CTGGATA-3' [272]	05/15=33.3%	40
	5'-AATTAGTGA-CTGGAT-3' [273]	05/15=33.3%	40
	5'-AAATTAGTGA-CTGGA-3' [274]	05/15=33.3%	40
	5'-GAAATTAGTGA-CTGG-3' [275]	06/15=40.0%	42
25	-----		
16 mer exon-spanning probes			
position 1063-1078; 1064-1079; 1065-1080; 1066-1081; 1067-1082; 1068-1083; 1069-1084			
30	-----		
	probe	GC content	Tm
	5'-AGTGA-CTGGATATATT-3' [276]	05/16=31.3%	42
	5'-TAGTGA-CTGGATATAT-3' [277]	05/16=31.3%	42
	5'-TTAGTGA-CTGGATATA-3' [278]	05/16=31.3%	42
	5'-ATTAGTGA-CTGGATAT-3' [279]	05/16=31.3%	42
35	5'-AATTAGTGA-CTGGATA-3' [280]	05/16=31.3%	42
	5'-AAATTAGTGA-CTGGAT-3' [281]	05/16=31.3%	42
	5'-GAAATTAGTGA-CTGGA-3' [282]	06/16=37.5%	44
17 mer exon-spanning probes			
40	position 1063-1079; 1064-1080; 1065-1081; 1066-1082; 1067-1083; 1068-1084		

	probe	GC content	Tm
45	5'-TAGTGA-CTGGATATATT-3' [283]	05/17=29.4%	44
	5'-TTAGTGA-CTGGATATAT-3' [284]	05/17=29.4%	44
	5'-ATTAGTGA-CTGGATATA-3' [285]	05/17=29.4%	44
	5'-AATTAGTGA-CTGGATAT-3' [286]	05/17=29.4%	44
	5'-AAATTAGTGA-CTGGATA-3' [287]	05/17=29.4%	44
	5'-GAAATTAGTGA-CTGGAT-3' [288]	06/17=35.3%	46

Table 3: Potential exon-bridging oligomers (continued)

18 mer exon-spanning probes

position 1063-1080; 1064-1081; 1065-1082; 1066-1083; 1067-1084

5

probe	GC content	Tm
5'-TTAGTGA-CTGGATATATT-3' [289]	05/18=27.8%	46
5'-ATTAGTGA-CTGGATATAT-3' [290]	05/18=27.8%	46
5'-AATTAGTGA-CTGGATATA-3' [291]	05/18=27.8%	46
5'-AAATTAGTGA-CTGGATAT-3' [292]	05/18=27.8%	46
5'-GAAATTAGTGA-CTGGATA-3' [293]	06/18=33.3%	48

19 mer exon-spanning probes

position 1063-1081; 1064-1082; 1065-1083; 1066-1084

15

probe	GC content	Tm
5'-ATTAGTGA-CTGGATATATT-3' [294]	05/19=26.3%	48
5'-AATTAGTGA-CTGGATATAT-3' [295]	05/19=26.3%	48
5'-AAATTAGTGA-CTGGATATA-3' [296]	05/19=26.3%	48
5'-GAAATTAGTGA-CTGGATAT-3' [297]	06/19=31.6%	50

20

20 mer exon-spanning probes

position 1063-1082; 1064-1083; 1065-1084

25

probe	GC content	Tm
5'-AATTAGTGA-CTGGATATATT-3' [298]	05/20=25.0%	50
5'-AAATTAGTGA-CTGGATATAT-3' [299]	05/20=25.0%	50
5'-GAAATTAGTGA-CTGGATATA-3' [300]	06/20=30.0%	52

30

21 mer exon-spanning probes

position 1063-1083; 1064-1084

35

probe	GC content	Tm
5'-AAATTAGTGA-CTGGATATATT-3' [301]	05/21=23.8%	52
5'-GAAATTAGTGA-CTGGATATAT-3' [302]	06/21=28.6%	54

22 mer exon-spanning probes

position 1063-1084

40

probe	GC content	Tm
5'-GAAATTAGTGA-CTGGATATATT-3' [303]	06/22=27.3%	56°C 29

25 mer exon-spanning probes

position 1061-1085

45

probe	GC content	Tm
5'-GGAAATTAGTGA-CTGGATATATTAA-3' [304]	07/25=28.0%	64°C

Table 3: Potential exon-bridging oligomers (continued)H. EXON 08→09 exon-bridging oligomers

5 5'-TTCCATCTGAAG-CTTTTATTGGGAGA-3' [305]

15 mer exon-spanning probes

position 1207-1221; 1208-1222; 1209-1223; 1210-1224; 1211-1225; 1212-1226; 1213-1227; 1214-1228

10	probe	GC content	Tm
	5'-GAAG-CTTTTATTGGG-3' [306]	06/15=40.0%	42
	5'-TGAAG-CTTTTATTGG-3' [307]	05/15=33.3%	40
	5'-CTGAAG-CTTTTATTG-3' [308]	05/15=33.3%	40
15	5'-TCTGAAG-CTTTTATT-3' [309]	04/15=26.7%	38
	5'-ATCTGAAG-CTTTTAT-3' [310]	04/15=26.7%	38
	5'-CATCTGAAG-CTTTTA-3' [311]	05/15=33.3%	40
	5'-CCATCTGAAG-CTTTT-3' [312]	06/15=40.0%	42
20	5'-TCCATCTGAAG-CTTT-3' [313]	06/15=40.0%	42

16 mer exon-spanning probes

position 1207-1222; 1208-1223; 1209-1224; 1210-1225; 1211-1226; 1212-1227; 1213-1228

25	probe	GC content	Tm
	5'-TGAAG-CTTTTATTGGG-3' [314]	06/16=37.5%	44
	5'-CTGAAG-CTTTTATTGG-3' [315]	06/16=37.5%	44
	5'-TCTGAAG-CTTTTATTG-3' [316]	05/16=31.3%	42
	5'-ATCTGAAG-CTTTTATT-3' [317]	04/16=25.0%	40
30	5'-CATCTGAAG-CTTTTAT-3' [318]	05/16=31.3%	42
	5'-CCATCTGAAG-CTTTTA-3' [319]	06/16=37.5%	44
	5'-TCCATCTGAAG-CTTTT-3' [320]	06/16=37.5%	44

17 mer exon-spanning probes

35 position 1207-1223; 1208-1224; 1209-1225; 1210-1226; 1211-1227; 1212-1228

40	probe	GC content	Tm
	5'-CTGAAG-CTTTTATTGGG-3' [321]	07/17=41.2%	48
	5'-TCTGAAG-CTTTTATTGG-3' [322]	06/17=35.3%	46
	5'-ATCTGAAG-CTTTTATTG-3' [323]	05/17=29.4%	44
	5'-CATCTGAAG-CTTTTATT-3' [324]	05/17=29.4%	44
	5'-CCATCTGAAG-CTTTTAT-3' [325]	06/17=35.3%	46
45	5'-TCCATCTGAAG-CTTTTA-3' [326]	06/17=35.3%	46

18 mer exon-spanning probes

position 1207-1224; 1208-1225; 1209-1226; 1210-1227; 1211-1228

Table 3: Potential exon-bridging oligomers (continued)

	probe	GC content	Tm
	5'-TCTGAAG-CTTTTATTGGG-3' [327]	06/18=33.3%	48
5	5'-ATCTGAAG-CTTTTATTGG-3' [328]	06/18=33.3%	48
	5'-CATCTGAAG-CTTTTATTG-3' [329]	06/18=33.3%	48
	5'-CCATCTGAAG-CTTTTATT-3' [330]	06/18=33.3%	48
	5'-TCCATCTGAAG-CTTTTATT-3' [331]	06/18=33.3%	48
10	19 mer exon-spanning probes position 1207-1225; 1208-1226; 1209-1227; 1210-1228		
	probe	GC content	Tm
	5'-ATCTGAAG-CTTTTATTGGG-3' [332]	07/19=36.8%	52
15	5'-CATCTGAAG-CTTTTATTGGA-3' [333]	07/19=36.8%	52
	5'-CCATCTGAAG-CTTTTATTG-3' [334]	07/19=36.8%	52
	5'-TCCATCTGAAG-CTTTTATT-3' [335]	06/19=31.6%	50
20	20 mer exon-spanning probes position 1207-1226; 1208-1227; 1209-1228		
	probe	GC content	Tm
	5'-CATCTGAAG-CTTTTATTGGG-3' [336]	08/20=40.0%	56
	5'-CCATCTGAAG-CTTTTATTGG-3' [337]	08/20=40.0%	56
25	5'-TCCATCTGAAG-CTTTTATTG-3' [338]	07/20=35.0%	54
	21 mer exon-spanning probes position 1207-1227; 1208-1228		
30	probe	GC content	Tm
	5'-CCATCTGAAG-CTTTTATTGGG-3' [339]	09/21=42.9%	60
	5'-TCCATCTGAAG-CTTTTATTGG-3' [340]	08/21=38.1%	58
35	22 mer exon-spanning probes position 1207-1228		
	probe	GC content	Tm
	5'-TCCATCTGAAG-CTTTTATTGGG-3' [341]	09/22=40.9%	62°C 39
40	25 mer exon-spanning probes position 1205-1229		
45	probe	GC content	Tm
	5'-TTCCATCTGAAG-CTTTTATTGGGAG-3' [342]	10/25=40.0%	70°C

Table 3: Potential exon-bridging oligomers (continued)**I. EXON 09-10 exon-bridging oligomers**

5 5'-CCTCAACAATGT-CTTCCCCAACGTAG-3' [343]

15 mer exon-spanning probes

position 1375-1389; 1376-1390; 1377-1391; 1378-1392; 1379-1393; 1380-1394; 1381-1395; 1382-1396

10	probe	GC content	Tm
	5'-ATGT-CTTCCCCAACG-3' [344]	08/15=53.3%	46
	5'-AATGT-CTTCCCCAAC-3' [345]	07/15=46.7%	44
	5'-CAATGT-CTTCCCCAA-3' [346]	07/15=46.7%	44
15	5'-ACAATGT-CTTCCCCA-3' [347]	07/15=46.7%	44
	5'-ACAATGT-CTTCCCC-3' [348]	07/15=46.7%	44
	5'-CAACAATGT-CTTCCC-3' [349]	07/15=46.7%	44
	5'-TCAACAATGT-CTTCC-3' [350]	06/15=40.0%	42
20	5'-CTCAACAATGT-CTTC-3' [351]	06/15=40.0%	42

16 mer exon-spanning probes

position 1375-1390; 1376-1391; 1377-1392; 1378-1393; 1379-1394; 1380-1395; 1381-1396

25	probe	GC content	Tm
	5'-AATGT-CTTCCCCAACG-3' [352]	08/16=50.0%	48
	5'-CAATGT-CTTCCCCAAC-3' [353]	08/16=50.0%	48
	5'-ACAATGT-CTTCCCCAA-3' [354]	07/16=43.8%	46
	5'-ACAATGT-CTTCCCCA-3' [355]	07/16=43.8%	46
30	5'-CAACAATGT-CTTCCCC-3' [356]	08/16=50.0%	48
	5'-TCAACAATGT-CTTCCC-3' [357]	07/16=43.8%	46
	5'-CTCAACAATGT-CTTCC-3' [358]	07/16=43.8%	46

17 mer exon-spanning probes

35 position 1375-1391; 1376-1392; 1377-1393; 1378-1394; 1379-1395; 1380-1396

40	probe	GC content	Tm
	5'-CAATGT-CTTCCCCAACG-3' [359]	09/17=52.9%	52
	5'-ACAATGT-CTTCCCCAAC-3' [360]	08/17=47.1%	50
	5'-ACAATGT-CTTCCCCAA-3' [361]	07/17=41.2%	48
	5'-CAACAATGT-CTTCCCCA-3' [362]	08/17=47.1%	50
	5'-TCAACAATGT-CTTCCCC-3' [363]	08/17=47.1%	50
45	5'-CTCAACAATGT-CTTCCC-3' [364]	08/17=47.1%	50

18 mer exon-spanning probes

position 1375-1392; 1376-1393; 1377-1394; 1378-1395; 1379-1396

Table 3: Potential exon-bridging oligomers (continued)

	probe	GC content	Tm
5	5'-ACAATGT-CTTCCCCAACG-3' [365]	09/18=50.0%	54
	5'-AACAATGT-CTTCCCCAAC-3' [366]	08/18=44.4%	52
	5'-CAACAATGT-CTTCCCCAA-3' [367]	08/18=44.4%	52
	5'-TCAACAATGT-CTTCCCCA-3' [368]	08/18=44.4%	52
	5'-CTCAACAATGT-CTTCCCC-3' [369]	09/18=50.0%	54
10	19 mer exon-spanning probes position 1375-1393; 1376-1394; 1377-1395; 1378-1396		
15	5'-AACAATGT-CTTCCCCAACG-3' [370]	09/19=47.4%	56
	5'-CAACAATGT-CTTCCCCAAC-3' [371]	09/19=47.4%	56
	5'-TCAACAATGT-CTTCCCCAA-3' [372]	08/19=42.1%	54
	5'-CTCAACAATGT-CTTCCCCA-3' [373]	09/19=47.4%	56
20	20 mer exon-spanning probes position 1375-1394; 1376-1395; 1377-1396		
25	5'-CAACAATGT-CTTCCCCAACG-3' [374]	10/20=50.0%	60
	5'-TCAACAATGT-CTTCCCCAAC-3' [375]	09/20=45.5%	58
	5'-CTCAACAATGT-CTTCCCCAA-3' [376]	09/20=45.5%	58
30	21 mer exon-spanning probes position 1375-1395; 1376-1396		
35	5'-TCAACAATGT-CTTCCCCAACG-3' [377]	10/21=47.6%	62
	5'-CTCAACAATGT-CTTCCCCAAC-3' [378]	10/21=47.6%	62
40	22 mer exon-spanning probes position 1375-1396		
45	5'-CTCAACAATGT-CTTCCCCAACG-3' [379]	11/22=50.0%	66°C
	25 mer exon-spanning probes position 1373-1397		
45	5'-CCTCAACAATGT-CTTCCCCAACGTA-3' [380]	12/25=48.0%	74°C

Note: "T" and "A" 5' of the exon-exon boundary of exons 02→03 and 06→07 do not match the genomic sequence, they match M27492.

CLAIMS

1. An *in vitro* method for increasing the synthesis of extracellular matrix compounds in a cell population by inhibiting the expression of IL1R1 characterised in that it comprises the step of contacting the cells with an IL1R1 exon-bridging antisense oligomer.
5
2. The method of claim 1, wherein said IL1R1 exon-bridging antisense oligomer is complementary to a sequence bridging exons 02-03 in the mature mRNA of the IL1R1 gene.
10
3. The method of claim 1 or 2, wherein said IL1R1 exon-bridging antisense oligomer comprises a sequence between 15 and 30 nucleotides and does not comprise a sequence of more than 11 consecutive nucleotides which are complementary to the sequence at the 3' end or the sequence at the 5' end of the exon-exon boundary in the mature mRNA of the IL1R1 gene.
15
4. The method of any one of claims 1 to 3, wherein said IL1R1 exon-bridging antisense oligomer is selected from a group consisting of probe NO: 6 (SEQ ID NO:6), probe NO:7 (SEQ ID NO:7), probe NO:8 (SEQ ID NO:8), probe NO:21 (SEQ ID NO:21) or a sequence having at least 70% sequence identity with the complementary sequence of the cDNA of the IL1R1 gene corresponding to probes NO:6, NO:7, NO:8 or probe NO:21.
20
5. The method of any one of claims 1 to 4, wherein said IL1R1 exon-bridging antisense oligomer comprises SEQ ID NO:7.
25
6. The method of claim 1, wherein said IL1R1 exon-bridging antisense oligomer is complementary to a sequence bridging exon 05-06 of the mature mRNA of the IL1R1 gene.
30
7. The method of claim 6, wherein said IL1R1 exon-bridging antisense oligomer is selected from a group consisting of probe NO: 24 (SEQ ID NO:24) or a

sequence having at least 70% sequence identity with the complementary sequence of the cDNA of the IL1R1 gene corresponding to probe NO:24.

8. An antisense oligomer for the inhibition of the expression of IL1R1 characterised in that said antisense oligomer is an exon-bridging antisense oligomer.
9. The antisense oligomer of claim 8, which is complementary to a sequence bridging exons 02-03 of the mature mRNA of the IL1R1 gene.
10. The antisense oligomer of claim 8 or 9, which comprises a sequence between 15 and 30 nucleotides and does not comprise a sequence of more than 11 consecutive nucleotides which are complementary to the sequence at the 3' end or the sequence at the 5' end of the exon-exon boundary in the mature mRNA of the IL1R1 gene.
11. The antisense oligomer of any one of claims 8 to 10, wherein said IL1R1 exon-bridging antisense oligomer is selected from a group consisting of probe NO: 6 (SEQ ID NO:6), probe NO:7 (SEQ ID NO:7), probe NO:8 (SEQ ID NO:8), probe NO:21 (SEQ ID NO:21) or a sequence having at least 70% sequence identity with the complementary sequence of the cDNA of the IL1R1 gene corresponding to probes NO:6, NO:7, NO:8 or SEQ ID NO:21.
12. The antisense oligomer of any one of claims 8 to 11, wherein said IL1R1 exon-bridging antisense oligomer comprises SEQ ID NO:7.
13. The antisense oligomer of claim 8, which is complementary to a sequence bridging exons 05-06 of the mature mRNA of the IL1R1 gene.
14. The antisense oligomer according to claim 13, wherein said IL1R1 exon-bridging antisense oligomer comprises SEQ ID NO:24.
15. The antisense oligomers of any one of claims 8 to 14 for use as a medicament.

16. A pharmaceutical composition comprising one or more antisense oligomers according to any one of claims 8 to 14 for the inhibition of the expression of IL1R1 and further comprising at least one pharmaceutically acceptable carrier.

5

17. The use of one or more antisense oligomers according to any one of claims 8 to 14 for the preparation of a medicament for the treatment or prevention of a disease characterized by a cartilage or osteochondral defect.

10 18. The use of claim 17 wherein said disease is osteoarthritis.

19. The use of one or more antisense oligomers according to any one of claims 8 to 14 for the preparation of a medicament for the treatment or prevention of a disease selected from the group consisting of neuropathies, such as diabetic neuropathy, immune-mediated damage to the peripheral nervous system, heat hyperalgesia, Guillain-Barre syndrome, AIDS, bone disorders, such as osteoporosis caused by lymphomyeloid proliferative diseases, bone resorption, as occurring in a variety of diseases including osteoporosis, periodontal disease and rheumatoid arthritis, atheromatosis, coronary heart diseases, acute renal failure, asthma and nasal polyposis.

15

20

20. A method for the *in vitro* modulation of the expression of a target gene in a cell population with an antisense oligomer said method characterised in that mature mRNA function is inhibited by contacting the cells with an exon-bridging antisense oligomer directed against said mature mRNA.

25

21. The method of claim 20, wherein said exon-bridging antisense oligomer has a length of between 15-30 nucleotides.

30 22. The method according to claim 20 or 21, wherein the step of contacting the cells is performed in the absence of a DNA transfecting agent.

23. The method according to any one of claims 20 to 22, wherein the function of all mature mRNAs originating from said target gene is inhibited.

24. The method according to any one of claims 20 to 23, wherein the target gene is
5 Interleukin 1 Receptor type I (IL1RI).

25. The method according to any one of claims 20 to 24, wherein the complementary sequence of said exon-bridging antisense oligomer has less than 70% sequence identity with a nucleotide sequence other than the mature
10 mRNA or DNA of said target gene.

26. The method according to claim 20, wherein said exon-bridging antisense oligomer has a GC content of at least 45%.

15 27. The method according to any one of claims 20 to 26, wherein the sequences complementary to the 5' and 3' end of the exon-exon boundary of said mRNA of said target gene have a T_m of less than 32-36°C.

28. The method according to any one of claims 20 to 27, wherein said exon-
20 bridging antisense oligomer does not comprise a sequence of more than 11 consecutive nucleotides which are complementary to the sequence at the 3' end or the sequence at the 5' end of the exon-exon boundary in the mature mRNA of the target gene.

25 29. The method of any one of claims 20 to 28, wherein the sequence of said exon-bridging antisense oligomer sequence has at least 70 % sequence identity with the complementary sequence of the cDNA of said target gene.

30. The method according to any one of claims 20 to 29, which comprises
30 contacting said cells with 1 to 100 nM of said exon-bridging antisense oligomer.

31. The method according to any one of claims 20 to 29, which comprises contacting said cells with 1 to 10 nM of said exon-bridging antisense oligomer.
32. The method according to any one of claims 20 to 31, wherein said cells are
5 chondrocytes, chondrocyte precursors, fibrochondrocytes, or fibroblasts.
33. The method according to any one of claims 20 to 31, wherein said cells are osteoarthritic chondrocytes.
- 10 34. A method for producing an exon-bridging antisense oligomer for the inhibition of expression of a target gene comprising the steps of:
- 1) determining the exon-exon boundaries in the sequence of a spliced mRNA of said target gene,
 - 15 2) selecting a sequence with a length between 15 and 30 residues bridging an exon-exon boundary in the spliced mRNA of said target gene, said sequence comprising at its 5' end or 3' end at least 4 residues identical to a sequence 5' of said exon-exon boundary and, optionally said sequence comprising at its 3' or 5' end a maximum of 11 residues identical to the sequence 3' adjacent of said exon-exon boundary.
 - 20 3) producing an antisense oligomer which consists of a sequence which is has at least 70% sequence identity with a sequence complementary to the sequence selected in step 2.
35. A method according to claim 34 further wherein step 2 further comprises one or
25 more of the steps selected from the group consisting of:
- a) determining whether the GC content of said sequence determined under (2) is above 45 %, .
 - b) determining whether the T_m of each of the sequences 3' and 5' of the exon-exon boundary within said sequence is below 32-36°C,
 - 30 c) determining whether said oligomer has a sequence identity below 70% with mature mRNA other than the mature mRNA or DNA of the target gene;

And selecting the one or more sequences which fulfil the criteria of one or more of steps a to c.

5 36. A method of treatment for a disease characterized by the overexpression of IL1R1, which comprises administering to a patient an exon-bridging antisense probe directed to mature mRNA of IL1R1.

10 37. An *in vitro* method for increasing the synthesis of extracellular matrix compounds in a cell population by inhibiting the expression of IL1RI characterised in that it comprises the use of sequences complementary to the sequences bridging two coding exons in the cDNA of IL1R1.

1/5




Figure 1

2/5




Figure 2

3/5




Figure 3

4/5

hIL1RI genomic DNA:


coding exon 2 intron coding exon 3
 5'-TTACTATTGCGTGGTAAAgtaagagagg-----atTTTatTTtagAAATTCATCTTACTGCC-3'
 3'-AATGATAACGCACCATTcctttctctcc-----taaaataaaatcTTTAAGTAGAATGACGG-5'
 (SEQ ID NO:381)

hIL1RI primary RNA:

5' UUACUAUUGCGUGGUAAGguaagagagg-----auuuuauuuuagAAAUUCAUCUUACUGCC
 (SEQ ID NO: 382)

5' UUACUAUUGCGUGGUAAG-AAAUUCAUCUUACUGCC hIL1RI mature mRNA (SEQ ID NO:383)
 3'-ACGCACCATTc-TTTAAGTAGAA-5' hybridised antisense
 oligonucleotide (SEQ ID NO:384)

Figure 4

5/5**Figure 5**

R3074-PCT.txt
SEQUENCE LISTING

<110> Universiteit Gent
Verbruggen, August
Elewaut, Dirk
Wan, Jun

<120> NOVEL ANTISENSE OLIGOMERS AND USE THEREOF

<130> R3074-PCT

<150> US 60/508 959

<151> 2003-10-06

<160> 393

<170> PatentIn version 3.3

<210> 1

<211> 15

<212> DNA

<213> Homo sapiens

<400> 1

aaaaaaaaaa aaaaaa

15

<210> 2

<211> 15

<212> DNA

<213> Homo sapiens

<400> 2

cacgatgcct ttcac

15

<210> 3

<211> 15

<212> DNA

<213> Homo sapiens

<400> 3

aaagacctca ccctc

15

<210> 4

<211> 15

<212> DNA

<213> Homo sapiens

<400> 4

ggtatctgac ggtct

15

<210> 5

<211> 15

<212> DNA

<213> Homo sapiens

<400> 5

ggcattgttg ttgac

15

<210> 6

<211> 15

<212> DNA

<213> Homo sapiens

R3074-PCT.txt

<400> 6
gaattcctta ccacg 15

<210> 7
<211> 20
<212> DNA
<213> Homo sapiens

<400> 7
gatgaattcc ttaccacgca 20

<210> 8
<211> 24
<212> DNA
<213> Homo sapiens

<400> 8
taagatgaat tccttaccac gcaa 24

<210> 9
<211> 26
<212> DNA
<213> Homo sapiens

<400> 9
ctccaagaag aatatgaaag tggtac 26

<210> 10
<211> 26
<212> DNA
<213> Homo sapiens

<400> 10
ttctctggag gctgataaat gcaagg 26

<210> 11
<211> 26
<212> DNA
<213> Homo sapiens

<400> 11
ttgcgtggta agaaattcat cttact 26

<210> 12
<211> 26
<212> DNA
<213> Homo sapiens

<400> 12
acagtggat aaggattgca aacctc 26

<210> 13
<211> 26
<212> DNA
<213> Homo sapiens

<400> 13
atttattact ctagaggaaa acaaac 26

<210> 14

R3074-PCT.txt

<211> 26
<212> DNA
<213> Homo sapiens

<400> 14
ggaagtagac ttgggatccc agatac 26

<210> 15
<211> 26
<212> DNA
<213> Homo sapiens

<400> 15
agactattac agtgtggaaa atcctg 26

<210> 16
<211> 26
<212> DNA
<213> Homo sapiens

<400> 16
gttaatatat ccagtcacta atttcc 26

<210> 17
<211> 26
<212> DNA
<213> Homo sapiens

<400> 17
tctcccaata aaagcttcag atggaa 26

<210> 18
<211> 26
<212> DNA
<213> Homo sapiens

<400> 18
ctacgttggg gaagacattg ttgagg 26

<210> 19
<211> 26
<212> DNA
<213> Homo sapiens

<400> 19
gtaacacttt catattcttc ttggag 26

<210> 20
<211> 20
<212> DNA
<213> Homo sapiens

<400> 20
ttgcatttat cagcctccag 20

<210> 21
<211> 20
<212> DNA
<213> Homo sapiens

<400> 21

agatgaattt cttaccacgc 20

<210> 22
<211> 20
<212> DNA
<213> Homo sapiens

<400> 22
gtttgcaatc cttataccac 20

<210> 23
<211> 20
<212> DNA
<213> Homo sapiens

<400> 23
ttgttttcct ctagagtaat 20

<210> 24
<211> 20
<212> DNA
<213> Homo sapiens

<400> 24
atctgggatc ccaagtctac 20

<210> 25
<211> 20
<212> DNA
<213> Homo sapiens

<400> 25
attttccaca ctgtaatagt 20

<210> 26
<211> 20
<212> DNA
<213> Homo sapiens

<400> 26
aaattagtga ctggatatat 20

<210> 27
<211> 20
<212> DNA
<213> Homo sapiens

<400> 27
ccatctgaag cttttattgg 20

<210> 28
<211> 20
<212> DNA
<213> Homo sapiens

<400> 28
tcaacaatgt cttccccaac 20

<210> 29
<211> 20

R3074-PCT.txt

<212> DNA
 <213> Homo sapiens
 <400> 29
 ttatttttttc ttcacgttcc 20

<210> 30
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 30
 attttaattc tgaggcagta 20

<210> 31
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 31
 tatattgtca agaagtagag 20

<210> 32
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 32
 caatcacagg ccttgtgggt 20

<210> 33
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 33
 tgacattaca gatcaattgt 20

<210> 34
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 34
 ctccttcttt tgtttgcagg 20

<210> 35
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 35
 taccaatcat gtgcttctgg 20

<210> 36
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 36
 tatatgcgtc ataggtcttt 20

R3074-PCT.txt

<210> 37
<211> 20
<212> DNA
<213> Homo sapiens

<400> 37
ttacgttttc attaatagacc 20

<210> 38
<211> 17
<212> DNA
<213> Homo sapiens

<400> 38
tgtgtccaat cggtggc 17

<210> 39
<211> 15
<212> DNA
<213> Homo sapiens

<400> 39
ttatcagcct ccaga 15

<210> 40
<211> 15
<212> DNA
<213> Homo sapiens

<400> 40
tttatcagcc tccag 15

<210> 41
<211> 15
<212> DNA
<213> Homo sapiens

<400> 41
atttatcagc ctcca 15

<210> 42
<211> 15
<212> DNA
<213> Homo sapiens

<400> 42
catttatcag cctcc 15

<210> 43
<211> 15
<212> DNA
<213> Homo sapiens

<400> 43
gcatttatca gcctc 15

<210> 44
<211> 15
<212> DNA

R3074-PCT.txt

<213> Homo sapiens
 <400> 44
 tgcatttatc agcct 15

<210> 45
 <211> 15
 <212> DNA
 <213> Homo sapiens
 <400> 45
 ttgcatttat cagcc 15

<210> 46
 <211> 15
 <212> DNA
 <213> Homo sapiens
 <400> 46
 cttgcattta tcagc 15

<210> 47
 <211> 16
 <212> DNA
 <213> Homo sapiens
 <400> 47
 tttatcagcc tccaga 16

<210> 48
 <211> 16
 <212> DNA
 <213> Homo sapiens
 <400> 48
 atttatcagc ctccag 16

<210> 49
 <211> 16
 <212> DNA
 <213> Homo sapiens
 <400> 49
 catttatcag cctcca 16

<210> 50
 <211> 16
 <212> DNA
 <213> Homo sapiens
 <400> 50
 gcatttatca gcctcc 16

<210> 51
 <211> 16
 <212> DNA
 <213> Homo sapiens
 <400> 51
 tgcatttatc agcctc 16

R3074-PCT.txt

<210> 52
<211> 16
<212> DNA
<213> Homo sapiens

<400> 52
ttgcatttat cagcct 16

<210> 53
<211> 16
<212> DNA
<213> Homo sapiens

<400> 53
cttgcattta tcagcc 16

<210> 54
<211> 17
<212> DNA
<213> Homo sapiens

<400> 54
atttatcagc ctccaga 17

<210> 55
<211> 17
<212> DNA
<213> Homo sapiens

<400> 55
catttatcag cctccag 17

<210> 56
<211> 17
<212> DNA
<213> Homo sapiens

<400> 56
gcatttatca gcctcca 17

<210> 57
<211> 17
<212> DNA
<213> Homo sapiens

<400> 57
tgcatttatc agcctcc 17

<210> 58
<211> 17
<212> DNA
<213> Homo sapiens

<400> 58
ttgcatttat cagcctc 17

<210> 59
<211> 17
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 59
cttgcattta tcagcct 17

<210> 60
<211> 18
<212> DNA
<213> Homo sapiens

<400> 60
catttatcag cctccaga 18

<210> 61
<211> 18
<212> DNA
<213> Homo sapiens

<400> 61
gcatttatca gcctccag 18

<210> 62
<211> 18
<212> DNA
<213> Homo sapiens

<400> 62
tgcatttatc agcctcca 18

<210> 63
<211> 18
<212> DNA
<213> Homo sapiens

<400> 63
ttgcatttat cagcctcc 18

<210> 64
<211> 18
<212> DNA
<213> Homo sapiens

<400> 64
cttgcattta tcagcctc 18

<210> 65
<211> 19
<212> DNA
<213> Homo sapiens

<400> 65
gcatttatca gcctccaga 19

<210> 66
<211> 19
<212> DNA
<213> Homo sapiens

<400> 66
tgcatttatc agcctccag 19

R3074-PCT.txt

<210> 67	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 67	
ttgcatttat cagcctcca	19
<210> 68	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 68	
cttgcattta tcagcctcc	19
<210> 69	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 69	
tgcatttatc agcctccaga	20
<210> 70	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 70	
ttgcatttat cagcctccag	20
<210> 71	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 71	
cttgcattta tcagcctcca	20
<210> 72	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 72	
ttgcatttat cagcctccag a	21
<210> 73	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 73	
cttgcattta tcagcctcca g	21
<210> 74	
<211> 23	
<212> DNA	
<213> Homo sapiens	

R3074-PCT.txt

<400> 74
cttgcatTTA tcagcctcca gac 23

<210> 75
<211> 26
<212> DNA
<213> Homo sapiens

<400> 75
ccttgcatTTT atcagcctcc agagac 26

<210> 76
<211> 26
<212> DNA
<213> Homo sapiens

<400> 76
ccttgcatTTT atcagcctcc agagaa 26

<210> 77
<211> 26
<212> DNA
<213> Homo sapiens

<400> 77
agtaagatga atttcttacc acgcaa 26

<210> 78
<211> 15
<212> DNA
<213> Homo sapiens

<400> 78
atttcttacc acgca 15

<210> 79
<211> 15
<212> DNA
<213> Homo sapiens

<400> 79
aatttcttac cacgc 15

<210> 80
<211> 15
<212> DNA
<213> Homo sapiens

<400> 80
gaatttctta ccacg 15

<210> 81
<211> 15
<212> DNA
<213> Homo sapiens

<400> 81
tgaatttctt accac 15

<210> 82

R3074-PCT.txt

<211> 15
<212> DNA
<213> Homo sapiens

<400> 82
atgaatttct tacca 15

<210> 83
<211> 15
<212> DNA
<213> Homo sapiens

<400> 83
gatgaatttc ttacc 15

<210> 84
<211> 15
<212> DNA
<213> Homo sapiens

<400> 84
agatgaattt cttac 15

<210> 85
<211> 15
<212> DNA
<213> Homo sapiens

<400> 85
aagatgaatt tctta 15

<210> 86
<211> 16
<212> DNA
<213> Homo sapiens

<400> 86
aatttcttac cacgca 16

<210> 87
<211> 16
<212> DNA
<213> Homo sapiens

<400> 87
gaatttctta ccacgc 16

<210> 88
<211> 16
<212> DNA
<213> Homo sapiens

<400> 88
tgaatttctt accacg 16

<210> 89
<211> 16
<212> DNA
<213> Homo sapiens

<400> 89

R3074-PCT.txt

atgaatttct taccac 16

<210> 90
<211> 16
<212> DNA
<213> Homo sapiens

<400> 90
gatgaatttc ttacca 16

<210> 91
<211> 16
<212> DNA
<213> Homo sapiens

<400> 91
agatgaattt cttacc 16

<210> 92
<211> 16
<212> DNA
<213> Homo sapiens

<400> 92
aagatgaatt tcctac 16

<210> 93
<211> 17
<212> DNA
<213> Homo sapiens

<400> 93
gaatttctta ccacgca 17

<210> 94
<211> 17
<212> DNA
<213> Homo sapiens

<400> 94
tgaatttctt accacgc 17

<210> 95
<211> 17
<212> DNA
<213> Homo sapiens

<400> 95
atgaatttct taccacg 17

<210> 96
<211> 17
<212> DNA
<213> Homo sapiens

<400> 96
gatgaatttc ttaccac 17

<210> 97
<211> 17

R3074-PCT.txt

<212> DNA
<213> Homo sapiens

<400> 97
agatgaattt cttacca 17

<210> 98
<211> 17
<212> DNA
<213> Homo sapiens

<400> 98
aagatgaatt tcttacc 17

<210> 99
<211> 18
<212> DNA
<213> Homo sapiens

<400> 99
tgaatttctt accacgca 18

<210> 100
<211> 18
<212> DNA
<213> Homo sapiens

<400> 100
atgaatttct taccacgc 18

<210> 101
<211> 18
<212> DNA
<213> Homo sapiens

<400> 101
gatgaatttc ttaccacg 18

<210> 102
<211> 18
<212> DNA
<213> Homo sapiens

<400> 102
agatgaattt cttaccac 18

<210> 103
<211> 18
<212> DNA
<213> Homo sapiens

<400> 103
aagatgaatt tcttacca 18

<210> 104
<211> 19
<212> DNA
<213> Homo sapiens

<400> 104
atgaatttct taccacgca 19

R3074-PCT.txt

<210> 105
<211> 19
<212> DNA
<213> Homo sapiens

<400> 105
gatgaatttc ttaccacgc 19

<210> 106
<211> 19
<212> DNA
<213> Homo sapiens

<400> 106
agatgaattt cttaccacg 19

<210> 107
<211> 19
<212> DNA
<213> Homo sapiens

<400> 107
aagatgaatt tcttaccac 19

<210> 108
<211> 20
<212> DNA
<213> Homo sapiens

<400> 108
gatgaatttc ttaccacgca 20

<210> 109
<211> 20
<212> DNA
<213> Homo sapiens

<400> 109
agatgaattt cttaccacgc 20

<210> 110
<211> 20
<212> DNA
<213> Homo sapiens

<400> 110
aagatgaatt tcttaccacg 20

<210> 111
<211> 21
<212> DNA
<213> Homo sapiens

<400> 111
agatgaattt cttaccacgc a 21

<210> 112
<211> 21
<212> DNA

R3074-PCT.txt

<213> Homo sapiens
 <400> 112
 aagatgaatt tcttaccacg c 21

<210> 113
 <211> 22
 <212> DNA
 <213> Homo sapiens
 <400> 113
 aagatgaatt tcttaccacg ca 22

<210> 114
 <211> 26
 <212> DNA
 <213> Homo sapiens
 <400> 114
 agtaagatga atttcttacc acgcaa 26

<210> 115
 <211> 26
 <212> DNA
 <213> Homo sapiens
 <400> 115
 gaggtttgca atccttatac cactgt 26

<210> 116
 <211> 15
 <212> DNA
 <213> Homo sapiens
 <400> 116
 aatccttata ccact 15

<210> 117
 <211> 15
 <212> DNA
 <213> Homo sapiens
 <400> 117
 caatccttat accac 15

<210> 118
 <211> 15
 <212> DNA
 <213> Homo sapiens
 <400> 118
 gcaatcctta tacca 15

<210> 119
 <211> 15
 <212> DNA
 <213> Homo sapiens
 <400> 119
 tgcaatcctt atacc 15

R3074-PCT.txt

<210> 120
 <211> 15
 <212> DNA
 <213> Homo sapiens

 <400> 120
 ttgcaatcct tatac 15

 <210> 121
 <211> 15
 <212> DNA
 <213> Homo sapiens

 <400> 121
 tttgcaatcc ttata 15

 <210> 122
 <211> 15
 <212> DNA
 <213> Homo sapiens

 <400> 122
 gtttgcaatc cttat 15

 <210> 123
 <211> 15
 <212> DNA
 <213> Homo sapiens

 <400> 123
 ggtttgcaat cctta 15

 <210> 124
 <211> 16
 <212> DNA
 <213> Homo sapiens

 <400> 124
 caatccttat accact 16

 <210> 125
 <211> 16
 <212> DNA
 <213> Homo sapiens

 <400> 125
 gcaatcctta taccac 16

 <210> 126
 <211> 16
 <212> DNA
 <213> Homo sapiens

 <400> 126
 tgcaatcctt atacca 16

 <210> 127
 <211> 16
 <212> DNA
 <213> Homo sapiens

R3074-PCT.txt

<400> 127
ttgcaatcct tatacc 16

<210> 128
<211> 16
<212> DNA
<213> Homo sapiens

<400> 128
tttgcaatcc ttatac 16

<210> 129
<211> 16
<212> DNA
<213> Homo sapiens

<400> 129
gtttgcaatc cttata 16

<210> 130
<211> 16
<212> DNA
<213> Homo sapiens

<400> 130
ggtttgcaat cttat 16

<210> 131
<211> 17
<212> DNA
<213> Homo sapiens

<400> 131
gcaatcctta taccact 17

<210> 132
<211> 17
<212> DNA
<213> Homo sapiens

<400> 132
tgcaatcctt ataccac 17

<210> 133
<211> 16
<212> DNA
<213> Homo sapiens

<400> 133
tgcaatcctt atacca 16

<210> 134
<211> 17
<212> DNA
<213> Homo sapiens

<400> 134
tttgcaatcc ttatacc 17

R3074-PCT.txt

<210> 135
<211> 17
<212> DNA
<213> Homo sapiens

<400> 135
gtttgcaatc cttatac 17

<210> 136
<211> 17
<212> DNA
<213> Homo sapiens

<400> 136
ggtttgcaat ccttata 17

<210> 137
<211> 18
<212> DNA
<213> Homo sapiens

<400> 137
tgcaatcctt ataccact 18

<210> 138
<211> 18
<212> DNA
<213> Homo sapiens

<400> 138
ttgcaatcct tataccac 18

<210> 139
<211> 18
<212> DNA
<213> Homo sapiens

<400> 139
tttgcaatcc ttatacca 18

<210> 140
<211> 18
<212> DNA
<213> Homo sapiens

<400> 140
gtttgcaatc cttatacc 18

<210> 141
<211> 18
<212> DNA
<213> Homo sapiens

<400> 141
ggtttgcaat ccttatac 18

<210> 142
<211> 19
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 142 ttgcaatcct tataaccact	19
<210> 143 <211> 19 <212> DNA <213> Homo sapiens	
<400> 143 tttgcaatcc ttataccac	19
<210> 144 <211> 19 <212> DNA <213> Homo sapiens	
<400> 144 gtttgcaatc cttatacca	19
<210> 145 <211> 19 <212> DNA <213> Homo sapiens	
<400> 145 ggtttgcaat ccttatacc	19
<210> 146 <211> 20 <212> DNA <213> Homo sapiens	
<400> 146 tttgcaatcc ttataccact	20
<210> 147 <211> 20 <212> DNA <213> Homo sapiens	
<400> 147 gtttgcaatc cttataccac	20
<210> 148 <211> 20 <212> DNA <213> Homo sapiens	
<400> 148 ggtttgcaat ccttatacca	20
<210> 149 <211> 22 <212> DNA <213> Homo sapiens	
<400> 149 gtttgcaatc cttataccac tc	22
<210> 150	

R3074-PCT.txt

<211> 22
<212> DNA
<213> Homo sapiens

<400> 150
ggtttgcaat cttatacca cc 22

<210> 151
<211> 23
<212> DNA
<213> Homo sapiens

<400> 151
ggtttgcaat cttatacca ctc 23

<210> 152
<211> 26
<212> DNA
<213> Homo sapiens

<400> 152
gaggtttgca atccttatac cactgc 26

<210> 153
<211> 26
<212> DNA
<213> Homo sapiens

<400> 153
gtttgttttc ctctagagta ataaat 26

<210> 154
<211> 15
<212> DNA
<213> Homo sapiens

<400> 154
tcctctagag taata 15

<210> 155
<211> 15
<212> DNA
<213> Homo sapiens

<400> 155
ttcctctaga gtaat 15

<210> 156
<211> 15
<212> DNA
<213> Homo sapiens

<400> 156
tttcctctag agtaa 15

<210> 157
<211> 15
<212> DNA
<213> Homo sapiens

<400> 157

R3074-PCT.txt

ttttcctcta gagta 15

<210> 158
<211> 15
<212> DNA
<213> Homo sapiens

<400> 158
gttttcctct agagt 15

<210> 159
<211> 15
<212> DNA
<213> Homo sapiens

<400> 159
gttttcctct agagt 15

<210> 160
<211> 15
<212> DNA
<213> Homo sapiens

<400> 160
ttgttttcct ctaga 15

<210> 161
<211> 15
<212> DNA
<213> Homo sapiens

<400> 161
tttgttttcc tctag 15

<210> 162
<211> 16
<212> DNA
<213> Homo sapiens

<400> 162
ttcctctaga gtaata 16

<210> 163
<211> 16
<212> DNA
<213> Homo sapiens

<400> 163
tttcctctag agtaat 16

<210> 164
<211> 16
<212> DNA
<213> Homo sapiens

<400> 164
ttttcctcta gagtaa 16

<210> 165
<211> 16

R3074-PCT.txt

<212> DNA
<213> Homo sapiens

<400> 165
gttttcctct agagta 16

<210> 166
<211> 16
<212> DNA
<213> Homo sapiens

<400> 166
tgttttcctc tagagt 16

<210> 167
<211> 16
<212> DNA
<213> Homo sapiens

<400> 167
ttgttttcct ctagag 16

<210> 168
<211> 16
<212> DNA
<213> Homo sapiens

<400> 168
tttgttttcc tctaga 16

<210> 169
<211> 17
<212> DNA
<213> Homo sapiens

<400> 169
tttcctctag agtaata 17

<210> 170
<211> 17
<212> DNA
<213> Homo sapiens

<400> 170
ttttcctcta gagtaat 17

<210> 171
<211> 17
<212> DNA
<213> Homo sapiens

<400> 171
gttttcctct agagtaa 17

<210> 172
<211> 17
<212> DNA
<213> Homo sapiens

<400> 172
tgttttcctc tagagta 17

R3074-PCT.txt

<210> 173
<211> 17
<212> DNA
<213> Homo sapiens

<400> 173
ttgttttcct ctagagt 17

<210> 174
<211> 17
<212> DNA
<213> Homo sapiens

<400> 174
tttgttttcc tctagag 17

<210> 175
<211> 18
<212> DNA
<213> Homo sapiens

<400> 175
ttttcctcta gagtaata 18

<210> 176
<211> 18
<212> DNA
<213> Homo sapiens

<400> 176
gttttcctct agagtaat 18

<210> 177
<211> 18
<212> DNA
<213> Homo sapiens

<400> 177
tgttttcctc tagagtaa 18

<210> 178
<211> 18
<212> DNA
<213> Homo sapiens

<400> 178
ttgttttcct ctagagta 18

<210> 179
<211> 18
<212> DNA
<213> Homo sapiens

<400> 179
tttgttttcc tctagagt 18

<210> 180
<211> 19
<212> DNA

R3074-PCT.txt

<213> Homo sapiens
<400> 180
gttttcctct agagtaata 19

<210> 181
<211> 19
<212> DNA
<213> Homo sapiens
<400> 181
tgttttcctc tagagtaat 19

<210> 182
<211> 19
<212> DNA
<213> Homo sapiens
<400> 182
ttgttttcct ctagagtaa 19

<210> 183
<211> 19
<212> DNA
<213> Homo sapiens
<400> 183
tttgttttcc tctagagta 19

<210> 184
<211> 20
<212> DNA
<213> Homo sapiens
<400> 184
tgttttcctc tagagtaata 20

<210> 185
<211> 20
<212> DNA
<213> Homo sapiens
<400> 185
ttgttttcct ctagagtaat 20

<210> 186
<211> 20
<212> DNA
<213> Homo sapiens
<400> 186
tttgttttcc tctagagtaa 20

<210> 187
<211> 21
<212> DNA
<213> Homo sapiens
<400> 187
ttgttttcct ctagagtaat a 21

R3074-PCT.txt

<210> 188
<211> 21
<212> DNA
<213> Homo sapiens

<400> 188
tttgttttcc tctagagtaa t 21

<210> 189
<211> 22
<212> DNA
<213> Homo sapiens

<400> 189
tttgttttcc tctagagtaa ta 22

<210> 190
<211> 25
<212> DNA
<213> Homo sapiens

<400> 190
gtttgttttc ctctagagta ataaa 25

<210> 191
<211> 26
<212> DNA
<213> Homo sapiens

<400> 191
gtatctggga tcccaagtct acttcc 26

<210> 192
<211> 15
<212> DNA
<213> Homo sapiens

<400> 192
gatcccaagt ctact 15

<210> 193
<211> 15
<212> DNA
<213> Homo sapiens

<400> 193
ggatcccaag tctac 15

<210> 194
<211> 15
<212> DNA
<213> Homo sapiens

<400> 194
gggatcccaa gtcta 15

<210> 195
<211> 15
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 195
tgggatccca agtct 15

<210> 196
<211> 15
<212> DNA
<213> Homo sapiens

<400> 196
ctgggatccc aagtc 15

<210> 197
<211> 15
<212> DNA
<213> Homo sapiens

<400> 197
tctgggatcc caagt 15

<210> 198
<211> 15
<212> DNA
<213> Homo sapiens

<400> 198
atctgggatc ccaag 15

<210> 199
<211> 15
<212> DNA
<213> Homo sapiens

<400> 199
tatctgggat cccaa 15

<210> 200
<211> 16
<212> DNA
<213> Homo sapiens

<400> 200
ggatcccaag tctact 16

<210> 201
<211> 16
<212> DNA
<213> Homo sapiens

<400> 201
ggatcccaa gtctac 16

<210> 202
<211> 16
<212> DNA
<213> Homo sapiens

<400> 202
tgggatccca agtcta 16

R3074-PCT.txt

<210> 203
<211> 16
<212> DNA
<213> Homo sapiens

<400> 203
ctgggatccc aagtct 16

<210> 204
<211> 16
<212> DNA
<213> Homo sapiens

<400> 204
tctgggatcc caagtc 16

<210> 205
<211> 16
<212> DNA
<213> Homo sapiens

<400> 205
atctgggatc ccaagt 16

<210> 206
<211> 16
<212> DNA
<213> Homo sapiens

<400> 206
tatctgggat cccaag 16

<210> 207
<211> 17
<212> DNA
<213> Homo sapiens

<400> 207
gggatcccaa gtctact 17

<210> 208
<211> 17
<212> DNA
<213> Homo sapiens

<400> 208
tgggatccca agtctac 17

<210> 209
<211> 17
<212> DNA
<213> Homo sapiens

<400> 209
ctgggatccc aagtcta 17

<210> 210
<211> 17
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 210
tctgggatcc caagtct 17

<210> 211
<211> 17
<212> DNA
<213> Homo sapiens

<400> 211
atctgggatc ccaagtc 17

<210> 212
<211> 17
<212> DNA
<213> Homo sapiens

<400> 212
tatctgggat cccaagt 17

<210> 213
<211> 18
<212> DNA
<213> Homo sapiens

<400> 213
tgggatccca agtctact 18

<210> 214
<211> 18
<212> DNA
<213> Homo sapiens

<400> 214
ctgggatccc agtctac 18

<210> 215
<211> 18
<212> DNA
<213> Homo sapiens

<400> 215
tctgggatcc caagtcta 18

<210> 216
<211> 18
<212> DNA
<213> Homo sapiens

<400> 216
atctgggatc ccaagtct 18

<210> 217
<211> 18
<212> DNA
<213> Homo sapiens

<400> 217
tatctgggat cccaagtc 18

<210> 218

R3074-PCT.txt

<211> 19
<212> DNA
<213> Homo sapiens

<400> 218
ctgggatccc aagtctact

19

<210> 219
<211> 19
<212> DNA
<213> Homo sapiens

<400> 219
tctgggatcc caagtctac

19

<210> 220
<211> 19
<212> DNA
<213> Homo sapiens

<400> 220
atctgggatc ccaagtcta

19

<210> 221
<211> 19
<212> DNA
<213> Homo sapiens

<400> 221
tatctgggat cccaagtct

19

<210> 222
<211> 20
<212> DNA
<213> Homo sapiens

<400> 222
tctgggatcc caagtctact

20

<210> 223
<211> 20
<212> DNA
<213> Homo sapiens

<400> 223
atctgggatc ccaagtctac

20

<210> 224
<211> 20
<212> DNA
<213> Homo sapiens

<400> 224
tatctgggat cccaagtcta

20

<210> 225
<211> 21
<212> DNA
<213> Homo sapiens

<400> 225

R3074-PCT.txt

atctgggatc ccaagtctac t	21
<210> 226 <211> 21 <212> DNA <213> Homo sapiens	
<400> 226 tatctgggat cccaagtcta c	21
<210> 227 <211> 22 <212> DNA <213> Homo sapiens	
<400> 227 tatctgggat cccaagtcta ct	22
<210> 228 <211> 25 <212> DNA <213> Homo sapiens	
<400> 228 gtatctggga tccaagtct acttc	25
<210> 229 <211> 26 <212> DNA <213> Homo sapiens	
<400> 229 caggattttc cacactgtaa tagtct	26
<210> 230 <211> 15 <212> DNA <213> Homo sapiens	
<400> 230 cacactgtaa tagtc	15
<210> 231 <211> 15 <212> DNA <213> Homo sapiens	
<400> 231 ccacactgta atagt	15
<210> 232 <211> 15 <212> DNA <213> Homo sapiens	
<400> 232 ccacactgta atagt	15
<210> 233 <211> 15	

R3074-PCT.txt

<212> DNA
<213> Homo sapiens

<400> 233
ttccacactg taata 15

<210> 234
<211> 15
<212> DNA
<213> Homo sapiens

<400> 234
tttccacact gtaat 15

<210> 235
<211> 15
<212> DNA
<213> Homo sapiens

<400> 235
ttttccacac tgtaa 15

<210> 236
<211> 15
<212> DNA
<213> Homo sapiens

<400> 236
attttccaca ctgta 15

<210> 237
<211> 15
<212> DNA
<213> Homo sapiens

<400> 237
gattttccac actgt 15

<210> 238
<211> 16
<212> DNA
<213> Homo sapiens

<400> 238
ccacactgta atagtc 16

<210> 239
<211> 16
<212> DNA
<213> Homo sapiens

<400> 239
tccacactgt aatagt 16

<210> 240
<211> 16
<212> DNA
<213> Homo sapiens

<400> 240
ttccacactg taatag 16

R3074-PCT.txt

<210> 241
<211> 16
<212> DNA
<213> Homo sapiens

<400> 241
tttccacact gtaata 16

<210> 242
<211> 16
<212> DNA
<213> Homo sapiens

<400> 242
ttttccacac tgtaat 16

<210> 243
<211> 16
<212> DNA
<213> Homo sapiens

<400> 243
attttccaca ctgtaa 16

<210> 244
<211> 16
<212> DNA
<213> Homo sapiens

<400> 244
gattttccac actgta 16

<210> 245
<211> 17
<212> DNA
<213> Homo sapiens

<400> 245
tccacactgt aatagtc 17

<210> 246
<211> 17
<212> DNA
<213> Homo sapiens

<400> 246
ttccacactg taatagt 17

<210> 247
<211> 17
<212> DNA
<213> Homo sapiens

<400> 247
tttccacact gtaatag 17

<210> 248
<211> 17
<212> DNA

R3074-PCT.txt

<213> Homo sapiens
<400> 248
ttttccacac tgtaata 17

<210> 249
<211> 17
<212> DNA
<213> Homo sapiens
<400> 249
attttccaca ctgtaat 17

<210> 250
<211> 17
<212> DNA
<213> Homo sapiens
<400> 250
gattttccac actgtaa 17

<210> 251
<211> 18
<212> DNA
<213> Homo sapiens
<400> 251
ttccacactg taatagtc 18

<210> 252
<211> 18
<212> DNA
<213> Homo sapiens
<400> 252
tttccacact gtaatagt 18

<210> 253
<211> 18
<212> DNA
<213> Homo sapiens
<400> 253
ttttccacac tgtaatag 18

<210> 254
<211> 18
<212> DNA
<213> Homo sapiens
<400> 254
attttccaca ctgtaata 18

<210> 255
<211> 18
<212> DNA
<213> Homo sapiens
<400> 255
gattttccac actgtaat 18

R3074-PCT.txt

<210> 256
<211> 19
<212> DNA
<213> Homo sapiens

<400> 256
tttccacact gtaatagtc 19

<210> 257
<211> 19
<212> DNA
<213> Homo sapiens

<400> 257
ttttccacac tgtaatagt 19

<210> 258
<211> 19
<212> DNA
<213> Homo sapiens

<400> 258
attttccaca ctgtaatag 19

<210> 259
<211> 19
<212> DNA
<213> Homo sapiens

<400> 259
gattttccac actgtaata 19

<210> 260
<211> 20
<212> DNA
<213> Homo sapiens

<400> 260
ttttccacac tgtaatagtc 20

<210> 261
<211> 20
<212> DNA
<213> Homo sapiens

<400> 261
attttccaca ctgtaatagt 20

<210> 262
<211> 20
<212> DNA
<213> Homo sapiens

<400> 262
gattttccac actgtaatag 20

<210> 263
<211> 21
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 263
attttccaca ctgtaatagt c 21

<210> 264
<211> 21
<212> DNA
<213> Homo sapiens

<400> 264
gattttccac actgtaatag t 21

<210> 265
<211> 23
<212> DNA
<213> Homo sapiens

<400> 265
gattttccac actgtaatag tcc 23

<210> 266
<211> 26
<212> DNA
<213> Homo sapiens

<400> 266
caggattttc cacactgtaa tagtcc 26

<210> 267
<211> 26
<212> DNA
<213> Homo sapiens

<400> 267
ggaaattagt gactggatat attaac 26

<210> 268
<211> 15
<212> DNA
<213> Homo sapiens

<400> 268
gtgactggat atatt 15

<210> 269
<211> 15
<212> DNA
<213> Homo sapiens

<400> 269
agtgactgga tatat 15

<210> 270
<211> 15
<212> DNA
<213> Homo sapiens

<400> 270
tagtgactgg atata 15

R3074-PCT.txt

<210> 271
<211> 15
<212> DNA
<213> Homo sapiens

<400> 271
ttagtgactg gatat 15

<210> 272
<211> 15
<212> DNA
<213> Homo sapiens

<400> 272
attagtgact ggata 15

<210> 273
<211> 15
<212> DNA
<213> Homo sapiens

<400> 273
aattagtgac tggat 15

<210> 274
<211> 15
<212> DNA
<213> Homo sapiens

<400> 274
aaattagtg ctgga 15

<210> 275
<211> 15
<212> DNA
<213> Homo sapiens

<400> 275
gaaattagtg actgg 15

<210> 276
<211> 16
<212> DNA
<213> Homo sapiens

<400> 276
agtgactgga tatatt 16

<210> 277
<211> 16
<212> DNA
<213> Homo sapiens

<400> 277
tagtgactgg atatat 16

<210> 278
<211> 16
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 278
ttagtgactg gatata 16

<210> 279
<211> 16
<212> DNA
<213> Homo sapiens

<400> 279
attagtgact ggatat 16

<210> 280
<211> 16
<212> DNA
<213> Homo sapiens

<400> 280
aattagtgac tggata 16

<210> 281
<211> 16
<212> DNA
<213> Homo sapiens

<400> 281
aaattagtgat ctggat 16

<210> 282
<211> 16
<212> DNA
<213> Homo sapiens

<400> 282
gaaattagtg actgga 16

<210> 283
<211> 17
<212> DNA
<213> Homo sapiens

<400> 283
tagtgactgg atatatt 17

<210> 284
<211> 17
<212> DNA
<213> Homo sapiens

<400> 284
ttagtgactg gatatat 17

<210> 285
<211> 17
<212> DNA
<213> Homo sapiens

<400> 285
attagtgact ggatata 17

<210> 286

R3074-PCT.txt

<211> 17
 <212> DNA
 <213> Homo sapiens

<400> 286
 aattagtgac tggatat 17

<210> 287
 <211> 17
 <212> DNA
 <213> Homo sapiens

<400> 287
 aaattagtg ctggata 17

<210> 288
 <211> 17
 <212> DNA
 <213> Homo sapiens

<400> 288
 gaaattagtg actggat 17

<210> 289
 <211> 18
 <212> DNA
 <213> Homo sapiens

<400> 289
 ttagtgactg gatata 18

<210> 290
 <211> 18
 <212> DNA
 <213> Homo sapiens

<400> 290
 attagtgact ggatat 18

<210> 291
 <211> 18
 <212> DNA
 <213> Homo sapiens

<400> 291
 aattagtgac tggatata 18

<210> 292
 <211> 18
 <212> DNA
 <213> Homo sapiens

<400> 292
 aaattagtg ctggatat 18

<210> 293
 <211> 18
 <212> DNA
 <213> Homo sapiens

<400> 293

R3074-PCT.txt

gaaattagtg actggata 18

<210> 294
<211> 19
<212> DNA
<213> Homo sapiens

<400> 294
attagtgact ggatatatt 19

<210> 295
<211> 19
<212> DNA
<213> Homo sapiens

<400> 295
aattagtgac tggatatat 19

<210> 296
<211> 19
<212> DNA
<213> Homo sapiens

<400> 296
aaattagtgactggatatata 19

<210> 297
<211> 19
<212> DNA
<213> Homo sapiens

<400> 297
gaaattagtg actggatat 19

<210> 298
<211> 20
<212> DNA
<213> Homo sapiens

<400> 298
aattagtgac tggatatatt 20

<210> 299
<211> 20
<212> DNA
<213> Homo sapiens

<400> 299
aaattagtgactggatatata 20

<210> 300
<211> 20
<212> DNA
<213> Homo sapiens

<400> 300
gaaattagtg actggatatata 20

<210> 301
<211> 21

R3074-PCT.txt

<212> DNA
<213> Homo sapiens

<400> 301
aaattagtga ctggatatat t 21

<210> 302
<211> 21
<212> DNA
<213> Homo sapiens

<400> 302
gaaattagtg actggatata t 21

<210> 303
<211> 23
<212> DNA
<213> Homo sapiens

<400> 303
gaaattagtg actggatata ttc 23

<210> 304
<211> 26
<212> DNA
<213> Homo sapiens

<400> 304
ggaaattagtg gactggatat attaac 26

<210> 305
<211> 26
<212> DNA
<213> Homo sapiens

<400> 305
ttccatctga agcttttatt gggaga 26

<210> 306
<211> 15
<212> DNA
<213> Homo sapiens

<400> 306
gaagctttta ttggg 15

<210> 307
<211> 15
<212> DNA
<213> Homo sapiens

<400> 307
tgaagctttt attgg 15

<210> 308
<211> 15
<212> DNA
<213> Homo sapiens

<400> 308
ctgaagcttt tattg 15

R3074-PCT.txt

<210> 309
<211> 15
<212> DNA
<213> Homo sapiens

<400> 309
tctgaagctt ttatt 15

<210> 310
<211> 15
<212> DNA
<213> Homo sapiens

<400> 310
atctgaagct tttat 15

<210> 311
<211> 15
<212> DNA
<213> Homo sapiens

<400> 311
catctgaagc tttta 15

<210> 312
<211> 15
<212> DNA
<213> Homo sapiens

<400> 312
ccatctgaag ctttt 15

<210> 313
<211> 15
<212> DNA
<213> Homo sapiens

<400> 313
tccatctgaa gcttt 15

<210> 314
<211> 16
<212> DNA
<213> Homo sapiens

<400> 314
tgaagctttt attggg 16

<210> 315
<211> 16
<212> DNA
<213> Homo sapiens

<400> 315
ctgaagcttt tattgg 16

<210> 316
<211> 16
<212> DNA

R3074-PCT.txt

<213> Homo sapiens
<400> 316
tctgaagctt ttattg 16

<210> 317
<211> 16
<212> DNA
<213> Homo sapiens
<400> 317
atctgaagct tttatt 16

<210> 318
<211> 16
<212> DNA
<213> Homo sapiens
<400> 318
catctgaagc ttttat 16

<210> 319
<211> 16
<212> DNA
<213> Homo sapiens
<400> 319
ccatctgaag ctttta 16

<210> 320
<211> 16
<212> DNA
<213> Homo sapiens
<400> 320
tccatctgaa gctttt 16

<210> 321
<211> 17
<212> DNA
<213> Homo sapiens
<400> 321
ctgaagcttt tattggg 17

<210> 322
<211> 17
<212> DNA
<213> Homo sapiens
<400> 322
tctgaagctt ttattgg 17

<210> 323
<211> 17
<212> DNA
<213> Homo sapiens
<400> 323
atctgaagct tttattg 17

R3074-PCT.txt

<210> 324
<211> 17
<212> DNA
<213> Homo sapiens

<400> 324
catctgaagc ttttatt 17

<210> 325
<211> 17
<212> DNA
<213> Homo sapiens

<400> 325
ccatctgaag cttttat 17

<210> 326
<211> 17
<212> DNA
<213> Homo sapiens

<400> 326
tccatctgaa gctttta 17

<210> 327
<211> 18
<212> DNA
<213> Homo sapiens

<400> 327
tctgaagctt ttattggg 18

<210> 328
<211> 18
<212> DNA
<213> Homo sapiens

<400> 328
atctgaagct tttattgg 18

<210> 329
<211> 18
<212> DNA
<213> Homo sapiens

<400> 329
catctgaagc ttttattg 18

<210> 330
<211> 18
<212> DNA
<213> Homo sapiens

<400> 330
ccatctgaag cttttatt 18

<210> 331
<211> 18
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 331
tccatctgaa gcttttat 18

<210> 332
<211> 19
<212> DNA
<213> Homo sapiens

<400> 332
atctgaagct tttattggg 19

<210> 333
<211> 20
<212> DNA
<213> Homo sapiens

<400> 333
catctgaagc ttttattgga 20

<210> 334
<211> 19
<212> DNA
<213> Homo sapiens

<400> 334
ccatctgaag cttttattg 19

<210> 335
<211> 19
<212> DNA
<213> Homo sapiens

<400> 335
tccatctgaa gcttttatt 19

<210> 336
<211> 20
<212> DNA
<213> Homo sapiens

<400> 336
catctgaagc ttttattggg 20

<210> 337
<211> 20
<212> DNA
<213> Homo sapiens

<400> 337
ccatctgaag cttttattgg 20

<210> 338
<211> 20
<212> DNA
<213> Homo sapiens

<400> 338
tccatctgaa gcttttattg 20

R3074-PCT.txt

<210> 339
<211> 21
<212> DNA
<213> Homo sapiens

<400> 339
ccatctgaag cttttattgg g 21

<210> 340
<211> 21
<212> DNA
<213> Homo sapiens

<400> 340
tccatctgaa gcttttattg g 21

<210> 341
<211> 23
<212> DNA
<213> Homo sapiens

<400> 341
tccatctgaa gcttttattg ggc 23

<210> 342
<211> 26
<212> DNA
<213> Homo sapiens

<400> 342
ttccatctga agcttttatt gggagc 26

<210> 343
<211> 26
<212> DNA
<213> Homo sapiens

<400> 343
cctcaacaat gtcttcccca acgtag 26

<210> 344
<211> 15
<212> DNA
<213> Homo sapiens

<400> 344
atgtcttccc caacg 15

<210> 345
<211> 15
<212> DNA
<213> Homo sapiens

<400> 345
aatgtcttcc ccaac 15

<210> 346
<211> 15
<212> DNA
<213> Homo sapiens

R3074-PCT.txt

<400> 346
caatgtcttc cccaa 15

<210> 347
<211> 15
<212> DNA
<213> Homo sapiens

<400> 347
acaatgtctt cccca 15

<210> 348
<211> 15
<212> DNA
<213> Homo sapiens

<400> 348
aacaatgtct tcccc 15

<210> 349
<211> 15
<212> DNA
<213> Homo sapiens

<400> 349
caacaatgtc ttccc 15

<210> 350
<211> 15
<212> DNA
<213> Homo sapiens

<400> 350
tcaacaatgt cttcc 15

<210> 351
<211> 15
<212> DNA
<213> Homo sapiens

<400> 351
ctcaacaatg tcttc 15

<210> 352
<211> 16
<212> DNA
<213> Homo sapiens

<400> 352
aatgtcttcc ccaacg 16

<210> 353
<211> 16
<212> DNA
<213> Homo sapiens

<400> 353
caatgtcttc cccaac 16

<210> 354

R3074-PCT.txt

<211> 16
<212> DNA
<213> Homo sapiens

<400> 354
acaatgtctt ccccaa 16

<210> 355
<211> 16
<212> DNA
<213> Homo sapiens

<400> 355
aacaatgtct tcccca 16

<210> 356
<211> 16
<212> DNA
<213> Homo sapiens

<400> 356
caacaatgtc ttcccc 16

<210> 357
<211> 16
<212> DNA
<213> Homo sapiens

<400> 357
tcaacaatgt cttccc 16

<210> 358
<211> 16
<212> DNA
<213> Homo sapiens

<400> 358
ctcaacaatg tcttcc 16

<210> 359
<211> 17
<212> DNA
<213> Homo sapiens

<400> 359
caatgtcttc cccaacg 17

<210> 360
<211> 17
<212> DNA
<213> Homo sapiens

<400> 360
acaatgtctt cccaac 17

<210> 361
<211> 17
<212> DNA
<213> Homo sapiens

<400> 361

R3074-PCT.txt

aacaatgtct tccccaa 17

<210> 362
<211> 17
<212> DNA
<213> Homo sapiens

<400> 362
caacaatgtc ttcccca 17

<210> 363
<211> 17
<212> DNA
<213> Homo sapiens

<400> 363
tcaacaatgt cttcccc 17

<210> 364
<211> 17
<212> DNA
<213> Homo sapiens

<400> 364
ctcaacaatg tcttccc 17

<210> 365
<211> 18
<212> DNA
<213> Homo sapiens

<400> 365
acaatgtctt cccaacg 18

<210> 366
<211> 18
<212> DNA
<213> Homo sapiens

<400> 366
aacaatgtct tccccaac 18

<210> 367
<211> 18
<212> DNA
<213> Homo sapiens

<400> 367
caacaatgtc ttcccaa 18

<210> 368
<211> 18
<212> DNA
<213> Homo sapiens

<400> 368
tcaacaatgt cttcccca 18

<210> 369
<211> 18

R3074-PCT.txt

<212> DNA
<213> Homo sapiens

<400> 369
ctcaacaatg tcttcccc 18

<210> 370
<211> 19
<212> DNA
<213> Homo sapiens

<400> 370
aacaatgtct tccccaacg 19

<210> 371
<211> 19
<212> DNA
<213> Homo sapiens

<400> 371
caacaatgtc ttccccaac 19

<210> 372
<211> 19
<212> DNA
<213> Homo sapiens

<400> 372
tcaacaatgt cttcccaa 19

<210> 373
<211> 19
<212> DNA
<213> Homo sapiens

<400> 373
ctcaacaatg tcttcccca 19

<210> 374
<211> 20
<212> DNA
<213> Homo sapiens

<400> 374
caacaatgtc ttccccaacg 20

<210> 375
<211> 20
<212> DNA
<213> Homo sapiens

<400> 375
tcaacaatgt cttccccaac 20

<210> 376
<211> 20
<212> DNA
<213> Homo sapiens

<400> 376
ctcaacaatg tcttcccca 20

R3074-PCT.txt

<210> 377
 <211> 21
 <212> DNA
 <213> Homo sapiens
 <400> 377
 tcaacaatgt cttccccaac g 21

<210> 378
 <211> 21
 <212> DNA
 <213> Homo sapiens
 <400> 378
 ctcaacaatg tcttcccca c 21

<210> 379
 <211> 23
 <212> DNA
 <213> Homo sapiens
 <400> 379
 ctcaacaatg tcttcccca cgc 23

<210> 380
 <211> 26
 <212> DNA
 <213> Homo sapiens
 <400> 380
 cctcaacaat gtcttcccca acgtac 26

<210> 381
 <211> 57
 <212> DNA
 <213> Homo sapiens
 <400> 381
 ttactattgc gtggaaggt aagagaggat tttatttttag aaattcatct tactgcc 57

<210> 382
 <211> 57
 <212> RNA
 <213> Homo sapiens
 <400> 382
 uuacuauugc gugguaaggu aagagaggau uuuuuuuag aaaucaucu uacugcc 57

<210> 383
 <211> 35
 <212> RNA
 <213> Homo sapiens
 <400> 383
 uuacuauugc gugguaagaa auucaucuua cugcc 35

<210> 384
 <211> 22
 <212> DNA

R3074-PCT.txt

<213> Homo sapiens.
<400> 384
aagatgaatt tcttaccacg ca 22

<210> 385
<211> 26
<212> DNA
<213> Homo sapiens
<400> 385
ccttgcatTT atcagcctcc agagaa 26

<210> 386
<211> 26
<212> DNA
<213> Homo sapiens
<400> 386
agtaagatga atttcttacc acgcaa 26

<210> 387
<211> 26
<212> DNA
<213> Homo sapiens
<400> 387
gaggTTtgca atccttatac cactgt 26

<210> 388
<211> 26
<212> DNA
<213> Homo sapiens
<400> 388
gtttgttttc ctctagagta ataaat 26

<210> 389
<211> 26
<212> DNA
<213> Homo sapiens
<400> 389
gtatctggga tcccaagtct acttcc 26

<210> 390
<211> 26
<212> DNA
<213> Homo sapiens
<400> 390
caggattttc cacactgtaa tagtct 26

<210> 391
<211> 26
<212> DNA
<213> Homo sapiens
<400> 391
ggaaattagt gactggatat attaac 26

R3074-PCT.txt

<210> 392
<211> 26
<212> DNA
<213> Homo sapiens

<400> 392
ttccatctga agctttttatt gggaga

26

<210> 393
<211> 26
<212> DNA
<213> Homo sapiens

<400> 393
cctcaacaat gtcttcccca acgtag

26

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number
WO 2005/033694 A3

(51) International Patent Classification⁷: **G01N 31/00**,
A01N 43/00, A61K 31/70, C07H 21/02, 21/04, 21/00

(21) International Application Number:
PCT/BE2004/000142

(22) International Filing Date: 6 October 2004 (06.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/508,959 6 October 2003 (06.10.2003) US

(71) Applicant (for all designated States except US): **UNIVERSITEIT GENT** [BE/BE]; Sint-Pietersnieuwstraat 25, B-9000 Gent (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VERBRUGGEN, August** [BE/BE]; Zanddstraat 12, B-9810 Nazareth (BE). **ELEWAUT, Dirk** [BE/BE]; Victor Laureinstraat 21, B-9052 Gent (BE). **WAN, Jun** [CN/BE]; Brouwersstraat 105, B-3000 Leuven (BE).

(74) Agents: **BIRD, William, E.** et al.; Bird Goen & Co., Klein Dalenstraat 42A, B-3020 Winksele (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
20 October 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL ANTISENSE OLIGOMERS AND USE THEREOF

(57) Abstract: The invention relates to the use of a novel type of antisense oligomers for use in the *in vitro* or *in vivo* inhibition of gene expression of a target gene. These oligomers, called exon-bridging oligomers are complementary to those parts of a spliced mRNA which are derived from two adjacent exons in the primary RNA transcript, and are called exon-bridging antisense oligomers. These oligomers have no complementarity to genomic DNA. These oligomers can be used to perform antisense inhibition with less aspecific binding to genomic DNA. The exon-bridging oligomers are suitable for inhibiting Interleukin1 type I Receptor in, for instance, chondrocytes, and are suitable for the prevention or treatment of osteoarthritis.



WO 2005/033694 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/BE2004/000142

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N31/00 A01N43/00 A61K31/70 C07H21/02 C07H21/04
C07H21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, Sequence Search, BIOSIS, MEDLINE, EMBASE, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MIRAGLIA L ET AL: "INHIBITION OF INTERLEUKIN-1 TYPE I RECEPTOR EXPRESSION IN HUMAN CELL-LINES BY AN ANTISENSE PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE" INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD, NY, US, vol. 18, no. 4, 1996, pages 227-240, XP001002842 ISSN: 0192-0561 Abstract; Experimental procedures; p. 228, under "cell culture and oligonucleotide treatment of cells and Analysis of IL-1 receptor, type 1 and ICAM-1 mRNA levels; Table 1 p.230; Discussion. ----- -/-</p>	1-19,36, 37

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

16 February 2005

Date of mailing of the international search report

13. 09. 05

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Bretherick, J

INTERNATIONAL SEARCH REPORT

Inter:

tion No

PCT/BE2004/000142

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 856 099 A (MIRAGLIA ET AL) 5 January 1999 (1999-01-05) Columns 1 and 2; Examples 1-5, Table 1; Example 6-9. -----	1-19,36, 37
Y	BURCH R M ET AL: "OLIGONUCLEOTIDES ANTISENSE TO THE INTERLEUKIN 1 RECEPTOR MRNA BLOCKTHE EFFECTS OF INTERLEUKIN 1 IN CULTURED MURINE AND HUMAN FIBROBLASTS AND IN MICE" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 88, October 1991 (1991-10), pages 1190-1196, XP000925602 ISSN: 0021-9738 Abstract; p.1191, RH column, 2nd paragraph;Figs. 1 and 2; Discussion, esp. 1st 3 paragraphs. -----	1-19,36, 37
Y	DEMOOR J M ET AL: "ANTISENSE NUCLEIC ACIDS TARGETED TO THE THYMIDYLATE SYNTHASE (TS) MRNA TRANSLATION START SITE STIMULATE TS GENE TRANSCRIPTION" EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 243, 1998, pages 11-21, XP002923758 ISSN: 0014-4827 Introduction, Fig. 1; Results 1 1st paragraph; paragraph bridging pp. 14 and 15; p 18, LH column, 2nd sentence. -----	1-19,36, 37

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/BE2004/000142

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5856099	A	05-01-1999	AU	2993397 A	09-12-1997
			EP	0928419 A1	14-07-1999
			WO	9744656 A1	27-11-1997

INTERNATIONAL SEARCH REPORT

International application No.
PCT/BE2004/000142

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-19, 36, 37

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-19, 36,37

In vitro method for increasing the synthesis of extracellular matrix compounds in a cell population by inhibiting the expression of IL-1R1 characterised in that it comprises the step of contacting the cells with an IL-1R1 exon-bridging antisense oligomer; antisense oligomers for this purpose; their use in the preparation of medicaments.

2. claims: 20-35

Methods for the in vitro modulation of the expression of a target gene in a cell population with an antisense oligomer characterised in that mature mRNA function is inhibited by contacting the cells with an exon-bridging antisense oligomer directed against said mature mRNA; method of producing an exon-bridging antisense oligomer for the inhibition of expression of a target gene.
